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Multiple sclerosis (MS), considered the lead disease featuring demyelination [316], is the 
most common cause of non traumatic disability in young people. It is characterized by 
inflammation, progressive demyelination and gliosis, axonal injury and loss. The 
pathological hallmarks of all the subtypes of this disease are focal areas, called plaques, 
of demyelination in the CNS, with surrounding inflammation and neurodegeneration 
[223,224]. Despite its high prevalence, multiple sclerosis remains a challenging ailment 
to study. Currently the most widely accepted hypothesis concerning MS pathogenesis is 
the autoimmune hypothesis:  an autoimmune inflammation is proposed to be the cause of 
demyelination and auto-reactive leukocytes could be the disease initiators [225, 226].  
One of the therapeutic approaches that is currently being developed to improve the 
regenerative outcome involves the use of CNS reactive antibodies to promote 
remyelination [280]. One of these antibodies, rHIgM22, is able to bind to 
oligodendrocytes and myelin in vitro. Moreover, rHIgM22 is able to enter the CNS, 
accumulate at lesion site and promote remyelination in mouse models of chronical 
demyelination [289, 291]. As a matter of fact, this antibody has recently passed a phase I 
clinical trial for treatment of MS. 
Evidence suggests that the binding target of rHIgM22 could be associated with plasma 
membrane lipid rafts, and that lipid rafts might be involved in the signaling associated 
with the biological activity of this antibody [294, 295]. Moreover, it has been 
demonstrated that, isolated OPCs do not respond to rHIgM22 treatment, instead mixed 
glial cultures consisting of astrocytes, OPCs and microglial cells demonstrate observable 
rHIgM22-mediated OPC proliferation [299]. 
The aim of this study was to analyze the plasma membrane lipid rafts composition in 
MGC in order to evaluate the effects exerted by rHIgM22 on these cells after single dose 
treatment of various duration.  
The analysis of the lipids and proteins distribution in MGC fractions, obtained after 
discontinuous sucrose gradient centrifugation of cells, and the alteration on lipids and 
protein composition of MGC due to the rHIgM22 treatment have been tested using TLC 
immunostaining assays and western blot analysis.  
The results obtained show that the DRM fraction obtained from MGC was enriched in 
sphingolipids, in particular sphingomyelin and gangliosides together with Lyn, Caveolin 
1 and PrP(SAF32). On the contrary, phospholipids, in particular 
phosphatididylethanolamine and phosphatidic acid are enriched in the HD fraction, 
together with integrin αv and Akt. Furthermore we observed that rHIgM22 exerted an 
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effect on the expression of P-Src(Y416) family and Lyn, that show a significant decrease, 
and PDGFRα that shows a significant increase. Moreover, the rHIgM22 treatment also 
induces a decrease in the activity of the aSMase.    
We hypothesize that the treatment with IgM22 could elicit biological responses mediated 
by alterations of lipid-dependent membrane organization which result in a reorganization 
of Lyn, integrin αvβ3 and PDGFRα at the cell surface to form a signaling complex. The 
formation of this complex triggers Lyn activation which in turn promotes oligodendrocyte 
precursor cells (OPCs) survival and proliferation and an inhibition of the pro apoptotic 
signaling. Moreover, the increased activation of Lyn could determine a decrease in 
ASMase activity and consequently in ceramide generation, thus inhibiting pro-apoptotic 
signaling and/or organization of sphingolipid-dependent signaling platforms. 
The identification of the binding targets of this antibody, able to promote remyelination 
in validated mouse models of MS, and the characterization of their membrane 
microenvironment could significantly contribute to the reveal the signaling mechanisms 
underlying the biological activity of rHIgM22.  
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Glycosphingolipids 
Eukaryotic cell membranes, whose basic role is that of a physical barrier between the 
extracellular milieu and the intracellular environment, are composed of a lipid bilayer. 
The three major classes of lipids present in eukaryotic cells are sterols, glycerolipids, and 
sphingolipids. The biochemical and biophysical properties of these classes differ 
considerably and impact upon their function [1]. An accurate regulation of their 
composition is crucial for proper growth, division, and responses to environmental stimuli 
leading to a correct maintenance of the cellular homeostasis [2].  
 Glycerophospholipids, a family of amphipathic molecules distributed 
asymmetrically across the plasma membrane, are the most abundant lipids in 
eukaryotic cell membranes. They constitute the backbone of cellular membranes 
and also provide the membrane with a suitable environment, fluidity, and ion 
permeability[3]. In neural membranes, it is possible to find three major classes of 
glycerophospholipids: 1,2-diacyl glycerophospholipid, 1-alk-1-enyl-2-acyl 
glycerophospholipid or plasmalogen, and 1-alkyl-2-acyl glycerophospholipids; 
all have a glycerol backbone with a fatty acid, and a phosphobase (ethanolamine, 
inositol, choline, serine) [4].  
The most represented glycerophospholipids in mammal tissues are 
phosphatidylethanolamine (PE) phosphatidylcholine (PC), phosphatidylserine 
(PS), and phosphatidylinositol (PI; PtdIns). Phosphatidic acid (PA; PtdOH) is also 
present in all cell membranes and it is a precursor of all neural membrane 
glycerophospholipids. PA also acts as an intracellular second messenger 
regulating different signaling proteins [5, 6], including kinases, phosphatases, and 
also the transcription factor mTOR. Diacylglycerol (DAG), arachidonic acid, and 
phosphoinositides have been implicated as messengers for Ca2+ homeostasis and 
protein phosphorylation too [7-9]. 
 The sphingolipids structure and contains a sphingoid backbone, usually 
sphinganine or sphingosine (sphingosine: (2S, 3R, 4E)-2-aminooctadec-4-ene-
1,3-diol [10]. Additions or modifications to the sphingoid base lead to the 
production of a variety of members of the sphingolipid family, comprising 
ceramides (N-acylated), phytoceramides (phosphorylation in position 4), 
dihydroceramides (degree of saturation), sphingomyelins (ceramides with a 
phosphocholine polar group), cerebrosides (ceramides with an hexose polar 
group), sulfatides (sulfate esters of cerebrosides), globosides (containing more 
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than one sugar) and gangliosides (containing sialic acid). Since their discovery, 
sphingolipids have been found on virtually all eukaryotic biological membranes. 
Some sphingolipids have been also found in a small number of prokaryotic genera 
[11]. The contents and composition of sphingolipids modulate the biophysical 
properties of model membranes [12] and they can be packed in lipid phase 
separation defining 2D domains. The membrane properties defined by the specific 
content/composition in sphingolipids, or these defined domains, allow biological 
membranes to adapt to variations in temperature, pH, membrane tension, etc. 
Several authors have suggested that the changes in membrane properties promoted 
by the sphingolipid composition can trigger cell signaling, even though the link 
between physical properties and cell signaling is complicated due to the large 
number of components and the dynamic characteristic of the membranes [13]. 
However, besides their physical properties, sphingolipids have been also found to 
be bioactive molecules. The first study that promoted this conceptual shift 
appeared in the mid-eighties, when sphingosine has been shown to inhibit PKC 
activity [14]. Since then several downstream protein effectors have been described 
or suggested mainly for sphingosine, ceramide, ceramide-1-phosphate, 
glycosphingolipids, and sphingosine-1-phosphate [15-17]. Ceramides and 
sphingosine-1-phosphate are the most studied sphingolipids with regard to cell 
signaling, and they most often exert opposing biological functions [18]. Briefly, 
ceramides have been linked to cell death, cell cycle arrest and senescence. 
Conversely, sphingosine-1-phosphate has been linked to cell survival, 
proliferation, migration and protection from apoptosis [11]. Another important 
and complicating aspect of sphingolipid signaling is the compartimentalization of 
sphingolipid metabolism within the cells. In fact, not only different steps of the 
sphingolipid metabolic pathway take place in different compartments in the cell, 
but, at times, the same biochemical reaction takes place in different subcellular 
compartments thus defining discrete pools of sphingolipids in different organelles 
[19]. Moreover, to make it even more complicated, not all ceramides are the same. 
Researchers are realizing that differences in length and level of unsaturation of 
the acyl chain, additional hydroxylations, or modifications on the sphingoid 
backbone (e.g., sphingolipids derived from alternative amino acids) can produce 
concrete species that exert specific functions [19, 20]. 
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Figure 1. Representatives of the major lipid classes of eukaryotic cell membranes.  
 
Glycosphingolipids biosynthesis, trafficking and degradation 
Over the past few decades, the biochemical pathways of glycosphingolipids metabolism 
and the intracellular sites of synthesis and degradation, respectively in the endoplasmic 
reticulum/Golgi apparatus and lysosomes, have been extensively characterized [21, 22].  
The biosynthesis of canonical glycosphingolipids starts by the condensation of serine and 
palmitoyl-CoA into 3-ketosphinganine. This reaction occurs in the endoplasmic reticulum 
(ER) and it is catalyzed by the enzyme serine palmitoyl transferase (SPT), and it is 
followed by a reduction reaction yielding sphinganine. Other amino acids such as alanine 
and glycine can be used instead of serine, forming the atypical sphingolipids, leading to 
deoxy- and deoxymethyl-sphingolipids. It is also worth to mention that fatty acids other 
than palmitic acid can be found in sphingolipids. Thus, SPT can accept fatty acid-CoA 
other than palmitoyl-CoA resulting in sphingolipids with different alkyl chain length [23, 
24]. Still in the ER, the (dihydro) ceramide synthases (CerS1-6) N-acylate sphinganine 
with several possible coenzyme A-activated fatty acids resulting in dihydroceramides. 
The irreversible desaturation of the 4,5-trans double bond leads to the formation of 
ceramides [25]. Ceramides are an extended family of structurally related molecules, with 
a growing number of members [19]. 
Phosphatidylethanolamine (PE)
Glucosylceramide
Cholesterol
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In the Golgi, ceramide is converted into sphingomyelin (SM) by sphingomyelin synthase 
(SMS), or it is incorporated into the glycosphingolipid family by addition of glucosyl- or 
galactosyl-units, followed by addition of more sugar moieties resulting in more complex 
glycosphingolipids [26]. Golgi-located ceramides, sphingomyelins and 
glycosphingolipids are then transported to various locations within the cell, such as the 
plasma membrane. With phosphatidylcholine (PC), SM is one of the most abundant 
phospholipid in biological membranes. It is found enriched in the outer leaflet of the 
plasma membrane, where it plays important structural roles. The presence of SM 
increases the rigidity and compactness of the plasma membrane (PM). Moreover, SM is 
found to be associated with cholesterol, further packing the PM, and defining rigid 
platforms, which have been thought to cluster certain proteins, such as a membrane 
receptors [27-29]. 
In the middle of the 1990s, Hannun and colleagues demonstrated that sphingomyelinase 
activation was required for cell signaling downstream of TNF alpha and other biological 
effectors [30, 31]. This demonstrated that ceramides produced by hydrolysis of complex 
sphingolipids (sphingomyelin, cerebrosides, etc.) at the plasma membrane, mitochondria 
or in the endosome/lysosome compartment could be involved in cell signaling [32]. In 
the plasma membrane and other cellular compartments, SM can be hydrolyzed to 
ceramide by alkaline, acid or neutral sphingomyelinases (AlkSMase, aSMase and 
nSMase respectively). Because the total amount of SM is normally more than 10 times 
the amount of total ceramide in the cell, hydrolysis of small percentage of SM, is 
translated to major changes in ceramide levels. Ceramide generated by this pathway is 
further degraded into sphingosine, which, as we mentioned before, can follow different 
paths. 
A third pathway of ceramide generation involves the catabolism of sphingolipids to 
sphingosine, which can be reused through N-acylation to produce ceramide. Moreover 
ceramides can be further broken down into sphingosine by ceramidases (acid, neutral and 
alkaline). Again, small amounts of ceramide hydrolysis can produce significant increases 
in sphingosine levels. Sphingosine can be then transported to other cellular compartments 
and re-acylated into ceramide by CerSs in the ER-Golgi or by reverse activity of 
ceramidases in the mitochondria [33, 34]. Sphingosine can also be phosphorylated by 
sphingosine kinases (SKs) to sphingosine-1-phosphate (S1P), a well established bioactive 
lipid [35]. Consequently, ceramide comprises a family of related structures that are found 
in different organelles or cellular compartments, even though it is commonly treated as a 
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unique biological entity. Recently, it has become apparent that the different pools of 
ceramides (either molecularly different or residing in different organelles) might have 
great significance as they may exert distinct biological functions [19]. A fundamental 
approach to start dissecting the complexity of ceramide signaling is to learn about the 
enzymes that regulate ceramide generation, degradation and turnover, their cellular 
topology, their related biologies and the diseases arising from their dysregulation. A key 
tool to study the role, function and regulation of sphingolipid-regulating enzymes in 
health and disease is the development of chemical inhibitors 
While ceramide resides on intracellular organelles such as mitochondria, 
glycosphingolipids beyond GlcCer are not known to exist on membranes facing the 
cytoplasm [36, 37]. The biosynthesis of glycosphingolipids in the brain provides an 
example of how competing biosynthetic pathways can lead to glycan structural diversity 
[36]. Stepwise biosynthesis of GalCer and sulfatide occurs, in the brain, in 
oligodendrocytes, the myelinating cells of the central nervous system (CNS). Synthesis 
of GalCer and sulfatide, in the brain, is switched on at the onset of the terminal 
differentiation, and remains constant in mature oligodendrocytes [38]. Moreover, in rat 
brain, their synthesis is maximal at the developmental stage of most rapid myelination 
[39]. All this suggests that GalCer and sulfatide might represent not only structural 
components of the myelin sheath but also active players in myelin formation and 
maintenance [40]. Gangliosides, in contrast, are synthesized by all cells, with 
concentration of the different forms varying according to cell type. It is well known that 
during brain development there are marked changes in expression of glycoconjugates 
ranging from complex proteoglycans to gangliosides. The expression pattern shifts from 
simple gangliosides, like GM3 and GD3, to complex gangliosides, such as GM1, GD1a, 
GD1b, and GT1b, and this shift is mainly regulated by the differential expression and 
intracellular distribution of the enzymes required for the biosynthesis of these 
glycosphingolipids[41,42]. Moreover, multiple glycosyltransferases can compete for the 
same precursor. LacCer, for example, can act as a substrate for sialyltransferase I, which 
forms GM3, or for GalNAc transferase, which forms GA2 [43]. GM3, in turn, can be 
acted on by N-acetylgalactosaminyltransferase, forming GM2, or by sialyltransferase II, 
thereby forming GD3, the simplest “b-series” ganglioside [44, 45]. Due to the branch 
exclusivity, since sialyltransferases cannot convert a-series gangliosides to their b-series 
correspondent, the relative expression level of the final GSL products is determined by 
enzyme competition at each branch. The transfer of N-acetylgalactosamine to a-, b-, and 
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c-series gangliosides, converting GM3 into GM2, GD3 into GD2, or GT3 into GT2, is 
catalyzed by the same N-acetylgalactosaminyltransferase. Likewise, the transfer of 
galactose to GM2 to form GM1, to GD2 to from GD1b, or to GT2 to form GT1c is 
accomplished by a single galactosyltransferase [26]. An additional level of regulation 
may occur via stable association of different glycosphingolipid glycosyltransferases into 
functional “multiglycosyltransferase” complexes. The enzymes involved are thought to 
act concertedly on the growing glycosphingolipid without releasing intermediate 
structures, ensuring progression to the preferred end product [46].  
While sphingolipid synthesis occurs in membranes of the secretory pathway, their 
catabolism occurs predominantly in endosomes and lysosomes. After internalization, 
GSL-rich membrane portions fuse with early endosomes, where the GSLs destined for 
degradation are sorted through the formation of multivescicular bodies which reach the 
lysosomes. Following the fusion, glycosphingolipids are exposed to lysosomal hydrolases 
and, in vivo, they are eventually broken down to their individual components, which are 
available for reuse [47,48]. 
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Figure 2. Schematic biosynthetic pathway of glycosphingolipids. 
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Biological functions glycosphingolipids 
GSLs are essential for the proliferation, survival, and differentiation of eukaryotic cells 
within complex multicellular systems, as established in different studies performed on the 
role of glycosphingolipids using genetic, biophysical, biochemical and cell biology 
approaches. Various studies involving the analysis of genetically engineered mice 
provided a general framework for the understanding of the roles of glycosphingolipids in 
mammals and their vital importance in the life of cells that are dealing with a multifaceted 
extracellular reality. These studies revealed that ablation of either GlcCer synthase or of 
B4GALT-V, responsible for the synthesis of LacCer, leads to embryonic lethality[49, 50]. 
Moreover, mice lacking all ganglioside, as a result of the knockout of both GalNAcT and 
SAT-I genes, suffer severe lethality. These mice show enhanced cell apoptosis, perturbed 
axon-glia interactions and axonal degeneration [51], though, it still remains to be 
elucidated whether these phenotypes are the result of a functional deficiency or a 
consequence of the accumulation of substrate precursors.  
Glycosphingolipids are highly segregated, together with cholesterol, in lipid domains 
with specialized signaling functions [52]. Within the cell, they are highly asymmetrically 
enriched in the external leaflet of plasma membranes, with the oligosaccharide chain 
protruding toward the extracellular space, where the sugar residues can engage cis and 
trans interactions with a wide variety of cell surface and extracellular molecules [53]. The 
GSLs local concentration in the membrane affects these interactions. Direct lateral 
interactions (cis interactions) with plasma membrane proteins are strongly favored within 
a sphingolipid-enriched membrane domain [54], whereas in the case of trans interactions, 
it has been shown that recognition of lipid-bound oligosaccharides by soluble ligands (for 
example antibodies or toxins) or by complementary carbohydrates and by carbohydrate 
binding proteins (such as selectins or lectins) belonging to the interfacing membrane of 
adjacent cells is strongly affected by their degree of segregation (or dispersion)[55].  
This variety of interactions is reflected in the variety of roles of glycosphingolipids. GSLs, 
for example, act as receptors for bacteria and viruses. As a matter of fact, GM1 acts as a 
receptor for cholera toxin B subunit [56, 57], Gb3 acts as a receptor for verotoxins [58,59], 
whereas two of the surface proteins of influenza virus are aimed against the terminal 
Neu5Ac group on glycosphingolipids and glycoproteins of the human host [60]. Some 
pieces of evidence also suggest a receptor role for glycosphingolipids in HIV infections. 
The HIV adhesin gp120, in fact, binds to several GSLs, including GalCer, sulfatide [61, 
62], GM3, GD3 and also Gb3 [63,64]. 
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Glycosphingolipids have a role in the modulation of the immune response too. For 
example, the interdigitation of the acyl chains of long chain LacCer with the cytosolic 
leaflet of the bilayer, leading to Lyn kinase activation, has been strongly implicated in 
ligand activation of human neutrophils phagocytosis [65]. Moreover, LacCer has also 
been found to play a role in the induction of proinflammatory cytokines in both glial cells 
and neutrophils [66, 67], while gangliosides play a role in the modulation of the 
cytotoxicity of natural killer cells [68].  
Glycosphingolipids are also known to interact with growth factor receptors, to modulate 
cell growth, and, in many cases, to inhibit receptor-associated tyrosine kinases. An 
example of this is the interaction of ganglioside GM3 with the insulin receptor (IR). 
Accumulation of GM3 upon acquisition of insulin resistance leads not only to the 
displacement of IR from caveolin-1 complexes, required for  insulin signaling leading to 
the translocation of GLUT4 at the surface of normal adipocytes [69], but also to its 
sequestration in a complex with GM3 [70]. Another example is the epidermal growth 
factor receptor (EGFR) interaction with GM3. GM3 negatively regulates ligand-
stimulated autophosphorylation and dimerization of EGFR [71-73], and cross-talk of 
EGFR with integrin receptors [74] and PKCα [75], inhibiting EGFR-dependent cell 
proliferation and survival.  
Glycosphingolipids also play important roles in modulating several properties of tumor 
cells. Most tumor cells show altered glycosphingolipid patterns on their surface as well 
as abnormal sphingolipid signaling and increased glycosphingolipid biosynthesis, which 
together play a major role in tumor growth, angiogenesis, and metastasis [76, 77]. 
Glycosphingolipids are also known to play a role in the regulation of axonal growth. For 
example, gangliosides GD1a and GT1b, enriched in axonal rafts, act as MAG receptors 
in MAG-induced inhibition of axonal growth [78, 79].  
 
Glial cells in the central nervous system 
Glial cells in the mammalian adult central nervous system (CNS), are constituted by 
oligodendrocytes, astrocytes and microglia. These cells, together, are by far the most 
abundant cells in the nervous system, comprising about 60-90% of all cells in the human 
brain [80, 81]. The name glia derives from the Greek word meaning glue, reflecting the 
property of these cells to hold together the nervous system and, for a long time, they were 
thought only to support neurons passively. However, in the past few decades, evidence 
has shown that glia function as master regulators of the nervous system, providing 
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valuable support in synaptic plasticity, axonal function, and acting as integral mediators 
of neuronal connectivity. Moreover, in addition to development and aging, these cells 
also play important roles in repair and remyelination in CNS disease [82-86]. 
 
 
 
Figure 3. The major types of glia interacting with a neuron. Adapted from Allen and 
Barres 2009[80]. 
 
Oligodendrocytes  
In the CNS, the oligodendrocyte is the resident cell type responsible for the production of 
myelin that consists of oligodendroglial plasma membrane loops tightly wound 
concentrically around the axon. They arise from oligodendrocytes progenitor cells 
(OPCs), which are generated in the ventral neuroepithelium of the neural tube in early 
embryonic life, more specifically from the motor neuron progenitor (pMN) domain [87, 
88], and in the dorsal spinal cord and hindbrain/telencephalon of the brain in late 
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embryonic development and early post-natal life [89, 90]. These proliferative cells 
migrate into the developing white matter [91-93], exit the cell cycle, undergo 
differentiation into mature oligodendrocytes, and begin to express a subset of myelin-
associated proteins [94, 95] (Figure 4).  
OPCs can form either oligodendrocytes or astrocytes depending on the context [96, 97]. 
Once an OPC is committed to an oligodendroglial fate, it synthesizes large amounts of 
plasma membrane and extends multiple processes that individually wrap around axons 
generating a multilayered stack of membranes tightly attached at their cytosolic and 
external surfaces [98]. The thus formed myelin membrane provides electric insulation of 
axons and dictates the clustering of the sodium channels at the nodes of Ranvier and the 
organization of the node itself, allowing saltatory nerve conduction [99, 100]. In addition 
to these contributions to neuronal signaling, OLs also provide trophic support to neurons, 
and to long axons that may not receive adequate support from intra-axonal trafficking 
alone [85]. During the main phase of myelination, oligodendrocytes generate about 5,000-
50,000 µm2 of myelin surface area per cell per day [101], and this is accomplished by a 
remarkable synthesis and transport of myelin lipids. Moreover, by the time myelination 
is completed, oligodendrocytes have synthesized about 40% of the total lipids in the 
human brain [102]. 
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Figure 4. Oligodendrocyte maturation toward oligodendroglial lineage. Each stage is 
identifiable according to the increasing complexity in morphology, the ability to proliferate, 
migrate and differentiate, and the expression of specific antigens. Adapted from Barateiro 
et al, 2014 [103].  
 
 
Astrocytes 
Astrocytes, or astroglia, are the most abundant and heterogeneous glial population in the 
central nervous system. In fact they outnumber neurons by over five fold [104] . 
Astrocytes have a plethora of functions, comprising roles as regulators of CNS 
homeostasis, through control of ion, pH, and neurotransmitter metabolism, and roles in 
the development and maintenance of the blood brain barrier (BBB), and in synaptogenesis 
and myelination [105, 106]. They originate from the neural embryonic progenitor cells 
that line the lumen of the embryonic neural tube, although they can also be formed 
indirectly via radial glia [107]. Though the heterogeneity of these cells is quite complex, 
the classification by Cajal, based on morphological differences, is still in use. Based on 
this classification, two main subtypes of astrocytes exist. Type 1 astrocytes, also named 
protoplasmic astrocytes, are localized in the gray matter where they ensheath blood 
vessels and synapses to promote BBB and synapses functions [82]. Type 2 astrocytes, 
defined fibrous astrocytes, are found in the white matter and have small cell bodies and 
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processes aligned with myelinated fibers, which gives them an elongated morphology. 
They also contact the nodes of Ranvier and the blood vessels [82, 105, 108]. In addition 
to this, other morphologically distinct populations of astrocytes have been described 
[109]. Moreover, astrocytes can also be diverse in their ability, ranging from inactive 
(quiescent), which exist in the normal resting CNS, to active (reactive). Astrocytes 
become activated in response to all form of CNS insults (infection, trauma, ischemia, etc.) 
through a process defined as reactive astrogliosis [110].  
Recent evidence suggests a correlation between astroglial differentiation, during fetal 
cortical development, and lipid rafts, in particular phosphatidylglucoside-enriched lipid 
rafts (PGLRs). Phosphatidylglucoside (PtdGlc) is a glycoglycerolipid localized in the 
outer leaflet of the plasma membrane of several mammalian cell types, in particular in 
the brain, where it is highly expressed in the two neurogenic regions of the adult brain 
[111].  
 
Microglia 
Microglial cells are widely regarded as the resident immune cells of the brain, constantly 
scanning through the microenvironment with their long protrusions, readily sensing 
alterations in tissue homeostasis and integrity [112]. These cells, representing around 
10% of the total glial cells in the nervous tissue, are present ubiquitously in the CNS, even 
though they are more enriched in the grey matter than in the white matter[113]. Under 
non-pathological conditions, microglia cells are highly ramified. In the diseased brain 
however their morphology changes, becoming more amoeboid. Upon activation, 
microglia progressively changes aspect, increasing the size of the cell body, retracting 
protrusions, and expressing de novo or up-regulating distinct profiles of surface 
phenotypic antigens, leading to an increased motility and to the adoption of immune 
effectors functions. Moreover, reactive microglia produces pro-inflammatory mediators 
including nitric oxide, reactive oxygen species (ROS), tumor necrosis factor α (TNFα) 
and a wide variety of other inflammatory cytokines[114]. Under pathological conditions, 
microglial functions depend on the stimuli that led to their activation; moderate CNS 
damage elicits protection by microglia [115-117], while following an intensive acute 
activation (for example stroke) or chronic activation (typical of neurodegenerative 
diseases) these cells tend to become neurotoxic, thus impairing neuronal activity [118-
120].  
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The morphology and functions of microglia are highly affected by lipids, and changes in 
the composition of lipid rafts can lead to a decrease in the release of microparticles, which 
in turn leads to altered cell-cell communications [121]. Moreover, there is evidence 
showing that high levels of cholesterol increase the expression of pro-inflammatory genes 
in microglia [122], while polyunsaturated fatty acids seem to have an anti inflammatory 
effect on these cells [123]. Sulfatide is also able to induce a rapid activation of microglia. 
As a matter of fact, sulfatide released at brain lesions sites, following myelin damage, 
determines not only an increase in the activation of intracellular signaling pathways, 
including MAPKs and inflammation-associated transcription factors, but also an increase 
in the production of inflammatory cytokines and chemokines[124].  
In addition to contributing to the maintenance of the normal CNS functions and to their 
role as sensors of altered homeostatic conditions, microglia also regulates apoptosis and 
survival of developing neurons [125]. Moreover, microglia provides trophic support and 
promotes differentiation of astrocytes and oligodendrocytes. Furthermore, recent 
evidence suggests a possible role of microglia as multipotent stem cells able to 
differentiate into neurons, astrocytes and oligodendrocytes [126].  
 
Myelin: development, damage and repair  
 
Myelin composition 
The myelin membrane has a unique composition, characterized by an high lipid content, 
ranging between 73 and 81% of its total dry weight and a ratio of protein to lipid around 
1 to 186 [105] [127,128].  
All the major lipid classes are found in myelin, like in other membranes, however myelin 
still has a remarkably characteristic composition. In fact, while in most cell membranes 
the molar ratio of cholesterol, phospholipids and glycosphingolipids is 25:65:10, these 
ratios in myelin are in the range of 40:40:20 [129] which allows the close packing and 
tight organization of molecules within the membrane.  
The myelin membrane has a high level of cholesterol, at least 26% by weight [127, 
130,131], which, in contrast with other cell types, is synthesized using mainly ketone 
bodies as precursors instead of glucose [132]. The high level of cholesterol not only is 
necessary for myelin growth and compaction, but also provides stability to this membrane 
through the regulation of fluidity and permeability [132, 133]. Cholesterol is also 
necessary for correct myelin assembly, and the supply/synthesis of this molecule dictates 
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this process, suggesting that upstream signaling systems which drive myelin biogenesis 
could be coupled to cholesterol metabolism [133].  
The myelin membrane also has a high amount of ethanolamine plasmalogens, whose 
levels correlate with the degree of myelination and reach the highest point between 30 
and 40 years of age, when myelination is complete [134, 135]. The structural features of 
these ethanolamine plasmalogens, like the perpendicular orientation of the sn-2 acyl chain 
instead of the bent orientation it has in phosphatidylethanolamine, favors a closer 
alignment of both acyl chains in plasmalogens, thus decreasing the fluidity of the 
membrane. Moreover, the absence of a carbonyl oxygen at the sn-1 position determines 
an increased hydrophilicity, resulting in stronger intermolecular hydrogen bonding 
between the head groups [136, 137]. Considering this, one of the function of the high 
level of plasmalogens in myelin could be to increase the packing density and with it the 
stability of the membrane. There is also evidence suggesting that plasmalogens could 
have a role in protecting unsaturated membrane lipids against oxidation by singlet oxygen 
[138] and in providing lipid mediators for inflammatory reactions [139]. 
Gangliosides, brain-enriched sialic acid-containing glycosphingolipids, increase not only 
in amounts but also in complexity as the brain develops [42]. The most prominent shift 
in gangliosides levels occurs in the late stages of fetal development and extends into the 
first two years of human development, a period that coincides with the most active phase 
of myelination, and, while only small amounts of gangliosides are present in myelin (~1% 
of total lipids), they represent a major fraction of the neuronal membrane [134]. It is 
known that gangliosides are able to interact with several growth factor tyrosine kinase 
receptors, thus regulating their activity[140]. For example, GM3 binding to EGFR 
determines the inhibition of the receptor tyrosine kinase activity [71-73], and several 
gangliosides inhibit the dimerization of PDGFR [141]. In addition, FGF-2 is able to 
interact with several gangliosides [142]. Specific gangliosides in the local environment 
could therefore modulate the activity of receptors such as PDGFR and FGFR, which are 
known to influence proliferation and differentiation of oligodendrocyte progenitors[101, 
143]. Furthermore, two of the major axonal gangliosides, GD1a and GT1b, are involved 
in long term myelin stability via their trans interaction with the myelin-associated 
glycoprotein (MAG), leading to MAG-induced inhibition of axon outgrowth [78, 79,  
144].  
Another distinguishing feature of myelin lipid composition, perhaps the most striking, is 
the enrichment in galactolipids. Galactosylceramide and 3-O-sulfogalactosylceramide 
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(sulfatide), with long chain fatty acids, account for approximately 20% and 5% of myelin 
lipids respectively [145,146]. Their biosynthesis involves two sequential steps. The 
enzyme UDP-galactose:ceramide galactosyltransferase (CGT), localized in the luminal 
side of the ER, catalyzes the transfer of a galactose from UDP-galactose to ceramide, thus 
forming GalCer [147]. A subpopulation of GalCer is then transported to the Golgi 
apparatus where the 3’-phosphoadenosine-5’-phosphosulfate:cerebroside 
sulfotransferase (CST) enzyme catalyzes the addition of the sulfate group, to obtain 
sulfatide [40, 146, 148] .  
 
 
 
Figure 5. Structure and biosynthetic pathway of sulfatide, the major sulfoglycolipid in 
the nervous system. 3-O-sulfogalactosylceramide is highly heterogeneous in its fatty acid 
composition. The main fatty acids found in mature CNS myelin are long chain fatty acids 
(24:0 and 24:1), including a significant amount of 2-hydroxylated fatty acids. Sulfatide 
synthesis requires the addition of galactose from UDP-galactose (UDP-Gal) to ceramide, 
catalyzed by the UDP-galactose:ceramide galactosyltransferase (CGT, EC 2.4.1.45, encoded 
by the ugt8 gene), and the subsequent addition of the sulfate group by the enzyme 3’-
phosphoadenosine-5’-phosphosulfate:cerebroside sulfotransferase (CST, EC 2.8.2.11, 
encoded by the gal3st1 gene). 
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Following their synthesis, both lipids are transported to the outer leaflet of the plasma 
membrane [130], and, although they are not myelin-specific lipids, their enrichment in 
myelin, which is common feature of both CNS and peripheral nervous system (PNS) 
across species, is much higher than in any other tissue [40]. The abundance of 
galactosylceramide and sulfatide has led to the hypothesis that they could be involved in 
myelin formation and stabilization, and in oligodendrocyte development [149]. 
Therefore, to gain a better understanding of the role of GalCer and sulfatide, genetically 
altered animal models, CGT knock-out and CST knock-out respectively, have been 
established and analyzed.  
The CGT enzyme, responsible for the synthesis of galactosylceramide, is highly 
expressed in the actively myelinating CNS ad PNS [150, 151]. Even though the CGT 
knock-out mice cannot synthesize GalCer and sulfatide, they are still able to form myelin 
with an apparently normal structure, which could be due to a partial compensation of the 
loss of these galactolipids by synthesizing 2-hydroxylated glucosylceramide, usually not 
present in myelin. These animals, however, display a neuropathological phenotype, 
characterized by splaying of the hind limbs, tremors, and ataxic locomotion that 
progressively worsens, leading to death of most animals by the third month of age [149, 
152]. This phenotype is consistent with nerve conduction disruption despite the presence 
of compact myelin and, as a matter of fact, the action potential measured in the spinal 
cord of these mice is smaller and has a longer latency respect to wild type animals [149]. 
Moreover, while CGT (-/-) myelin is apparently normal, several ultrastructural 
abnormalities associated with myelination in the CNS have been identified. CNS myelin 
thickness is reduced, while nodal length is increased and lateral loops are widely spaced. 
The disorganization of the lateral loops suggests a disruption in the formation of the tight 
junctions, unsurprisingly since sulfatide is a prominent constituent of myelin tight 
junctions and the formation of these junctions may be dependent on the presence of 
sulfatide. Furthermore, at least one-third of the myelin processes in CGT knock-out mice 
retains oligodendrocyte cytoplasm, indicating presence of immature myelin in regions 
that appear as structurally mature myelin, and profiles of compact myelin frequently show 
more than two oligodendrocytic loops in a single internodal segment [153, 154]. Despite 
the presence of all these anomalies in CNS myelin, PNS myelin appears normal 
suggesting that galactolipids, less abundant in the PNS, might not be as essential in the 
formation and maintenance of the PNS myelin sheath structure [153, 155, 156].  
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The CGT (-/-) model, however, does not allow discrimination between the specific 
functions of GalCer and sulfatide, considering that in these mice they are both absent. To 
overcome this limitation, another model, the CST knock-out mice, was developed [157]. 
The CST knock-out mice are completely devoid of sulfatide, whereas other glycolipids 
in the brain, galactosylceramide included, are not significantly altered [158]. CST-
deficient mice are born healthy but, around 6 weeks of age, they start exhibiting hind limb 
weakness, followed by pronounced tremor and progressive ataxia. The phenotype of these 
mice is in fact similar to that of CGT knock-out mice, even though it is milder in terms 
of age of onset, life span and severity of symptoms which allows these mice to survive 
for more than one year[157]. CST knock-out mice produce compact myelin, even though 
its thickness is reduced, compared to that of wild type mice, and paranodal structure 
displays alterations similar to those of the CGT (-/-) mice. Whereas in young mice the 
myelin sheaths are rather stable, the node/paranode structure only moderately altered, and 
axon size is comparable to that of wild type mice, as they age these mice show nodal 
structure deterioration, myelin vacuolar degeneration and also reduction of axon caliber 
[159]. Furthermore, electron microscopy analysis of myelinated nerve fiber revealed 
disorganized termination of the lateral loops at the node of Ranvier [160]. CST (-/-) mice 
also exhibit a deterioration in the clustering of Na+ and K+ channels at the node[161]. In 
mutant mice Na+ channels concentrate in small regions, presumptive nodes of Ranvier, 
and the lengths of the clusters are occasionally higher than the ones present in the wild 
type mice. The K+ channels clusters instead accumulate in regions adjacent to the Na+ 
channels clusters in presumptive paranodal regions, whereas in normal CNS axons Na+ 
channels cluster at the node of Ranvier and the K+ channels concentrate in juxtaparanodal 
regions [161]. These alterations in localization and clustering of ion channels are present 
in both PNS and CNS and are accompanied by an altered distribution and expression of 
axonal proteins such as Caspr, contactin and NF155, suggesting that sulfatide might play 
a role in the trafficking or stabilization of this protein at paranodal level [161-163]. 
The loss of GalCer and sulfatide affects the proliferation and survival rate of 
oligodendrocyte precursors. CGT knock-out mice show a significant increase in 
cellularity in the spinal cord [156], while CST (-/-) mice exhibit an increased number of 
oligodendrocytes, which mature earlier and in higher number [164]. In CGT (-/-) mice 
this increase seems to be due to an increased terminal differentiation [164]. This is in 
contrast with the observation that in CST (-/-) mice the increase in oligodendrocyte 
population seems to be determined by an increased proliferation and by a reduced 
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apoptosis [165]. Taken together, the discrepancy in phenotype between CST- and CGT-
null mice suggests that GalCer does not only act as a precursor for sulfatide synthesis, but 
also has a distinct function. GalCer appears to be primarily involved in myelin formation 
and maturation, while sulfatide contributes to the long term stability of myelin structure, 
in particular affecting the integrity and stability of the nodal and paranodal regions.  
GalCer and sulfatide, or more precisely, GalCer- and sulfatide-rich domains in the 
oligodendrocyte membrane also regulate the co-clustering and lateral distribution of 
several myelin proteins, thus affecting the proliferation, differentiation and survival of 
oligodendrocytes [166]. In the early stages of myelin formation, only a few typical myelin 
proteins are associated with lipid rafts. However, by the mid-myelination stage, when 
GalCer and sulfatide are synthesized at detectable levels, the myelin/oligodendrocyte 
glycoprotein (MOG) and the proteolipid protein (PLP) tend to localize in lipid rafts, and 
subsequently, in the final stages of myelination MAG and myelin basic protein (MBP) 
are also translocated into lipid rafts [167-169]. In particular, sulfatide seems to be 
essential for the transport of PLP to myelin membranes, which is consistent with the 
observation that association of PLP is reduced in CGT (-/-) mice [170]. In addition, 
oligosaccharide-oligosaccharide trans interactions between GalCer and sulfatide present 
in the extracellular surfaces of the multilayered myelin membrane form a specialized 
“glycosynapse” which stabilizes the myelin sheath [171-174]. 
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Figure 6. Glycolipid-enriched membrane domains in myelin. Glycolipid–glycolipid and 
glycolipid–protein interactions play multiple roles in myelin formation, maintenance and 
functioning but also in axon-myelin stability and communication. GalCer and sulfatide on 
opposing surfaces of the myelin wrap interact with each other through trans carbohydrate–
carbohydrate interactions forming a “glycosynapse” causing transmembrane signaling which 
results in clustering of membrane domains and loss of cytoskeleton integrity, leading to 
compaction and formation of mature myelin. On the other hand, GD1a and GT1b 
gangliosides, enriched in axonal lipid rafts, interact with MAG resulting in transmembrane 
signaling. MAG can also interact with Nogo-R1 (NgR1) which in turn interacts with 
signaling molecules p75/TROY and LINGO-1, leading to RhoA activation and axon 
outgrowth inhibition. Lateral interaction of GD1a and GT1b with p75 is important for the 
organization of NgR1 complex.  
Adapted from Aureli et al, 2015 [175]. 
 
Glial cells interaction in CNS (re)myelination and demyelination 
The synthesis of myelin and the consequent ensheathment of axons by this multilamellar 
membrane restrict action potentials to short unmyelinated segments, namely the nodes of 
Ranvier. This provides the structural basis for saltatory action potential propagation, 
which in turn speeds up nerve conduction 10-20 times compared to non myelinated axons 
[176]. Myelin however is also important for axon maintenance and function [177]. 
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Moreover, the cross talk between oligodendrocytes and axons is necessary to maintain 
metabolic function of axons, cytoskeletal arrangement, axonal transport, trophic support, 
and ion channel organization [85, 177-181].  
Whereas the early postnatal human brain is mostly non-myelinated, CNS myelination 
increases progressively in a defined temporal and topographic sequence within the first 
two decades of life [182]. During development, oligodendrocytes progenitor cells 
(OPCs), highly proliferative, motile, bipolar cells, are the main source for mature 
oligodendrocytes and myelin. These cells originate in sequential waves in specific regions 
of the ventral and dorsal neuroepithelium of the spinal cord and brain before migrating 
and dispersing into the CNS [183, 184]. The majority of these cells undergo a series of 
changes triggered by first contact with the axonal membrane and characterized by a rapid 
increase in morphological complexity and expansion of uncompacted myelin membrane, 
ultimately leading to their differentiation into myelinating oligodendrocytes [185]. A 
small pool of OPCs, characterized by the expression of the surface antigens platelet 
derived growth factor α receptor (PDGFRα) and neural/glial antigen 2 (NG2), instead, 
remains undifferentiated and quiescent in the adult CNS [184] where they are involved in 
myelin repair in the injured or diseased CNS [186]. A number of CNS diseases damage 
or destroy myelin and oligodendrocytes, leading to demyelination. This pathological 
process is typically a consequence of either a direct insult aimed at the oligodendrocytes, 
or of primary axonal loss. The first, commonly referred to as primary demyelination, can 
be further divided in two categories from a clinical point of view: genetic abnormalities 
affecting glia (leukodystrophies), and inflammatory damage to myelin and 
oligodendrocytes (multiple sclerosis being the most representative) [187]. Following the 
loss of the myelin sheath, axons undergo several molecular reorganizations and 
physiological changes that ultimately result in axonal dysfunction, degeneration, and loss 
of sensory and motor function [188] and, regardless of causes or underlying mechanisms, 
the adult CNS has only a limited capability to repair damaged tissue. This limitation does 
not only involve neurons and their axons but also mature oligodendrocytes, unable to 
compensate for the myelin loss as they usually degenerate [189, 190]. However, 
demyelination often triggers a spontaneous myelin repair process, defined remyelination 
[187]. This process, mediated by OPCs that are recruited to differentiate and replace the 
lost oligodendrocytes [191], leads to myelin sheath restoration, reinstatement of saltatory 
conduction and functional recovery, and, ideally, it should recapitulate developmental 
myelination and tissue reconstruction should be complete. The myelin sheaths generated 
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during this process however are thinner and exhibit shorter internodes than the 
developmental ones [192, 193]. On the other hand, recent data suggests that at late time 
points of recovery newly remyelinated fibers have comparable internode length and 
thickness compared to their developmental counterparts [194]. 
As previously stated, the remyelination process is mediated by OPCs. In particular, 
NG2/PDGFRα-expressing adult progenitors are recruited to lesion sites and differentiate 
into mature oligodendrocytes able to remyelinate axons, thus restoring nerve conduction 
[195]. The efficacy of this process however is compromised and limited by the 
inflammatory and activated milieu surrounding the demyelinated lesions [196]. In 
multiple sclerosis, for example, changes in the CNS microenvironment during the 
progression of the pathology cause OPCs to gradually lose their ability to respond to 
myelin damage, thus limiting their remyelination capacity [197]. All the steps of the 
remyelination process (OPC activation, recruitment, differentiation and myelination) are 
tightly regulated by a plethora of extrinsic and intrinsic factors acting either as activators 
or inhibitors [198, 199]. In response to injury, adult OPCs undergo a switch from a 
quiescent state to an active one, corresponding to a regenerative phenotype. During this 
activation step, the progenitor cells become responsive to growth factors, cytokines and 
chemokines, enhancing their proliferation and recruitment to the demyelinated area. 
Moreover, several genes involved in oligodendrocyte development and differentiation are 
upregulated [200-203]. Astrocytes and microglia, both activated by injury, are the main 
source of the factors that induce the rapid activation of OPCs during demyelination. 
Astrocytes, for example, secret several soluble factors implicated in enhancing 
myelination, including platelet derived growth factor (PDGF) and basic fibroblast growth 
factor (FGF2) [185, 204-206], whereas microglia is able to induce chemotaxis of OPCs 
through the secretion of hepatocyte growth factor [207]. Following activation, OPCs, in 
addition to the ongoing proliferation, migrate to demyelinated areas. Concomitantly, 
macrophages and microglia begin the removal of the myelin debris, whose presence 
impairs remyelination [208,209]. Astrocytes also play a role in this clearance, by inducing 
the recruitment of microglia to the lesion site, a process regulated by the chemokine 
CXCL10 [210]. Once OPCs reach the demyelinated area, they must differentiate into 
remyelinating oligodendrocytes. To do so, they need to establish contact with the 
demyelinated axon, synthesize the myelin membrane and subsequently form the myelin 
sheath, a process that presents many similarities with the developmental myelination.  
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Figure 7. Phases of remyelination. Following demyelination, astrocytes and microglia 
activate, consequently leading to OPC activation. These activated OPC are then recruited and 
migrate toward the lesion area, while macrophages and microglia start to remove the myelin 
debris. In the final phase of remyelination, the recruited OPCs differentiate into mature 
oligodendrocytes, leading to the formation of a new myelin sheath. Adapted from Franklin 
et al, 2008 [187].  
 
FGF and IGF, secreted respectively by astrocytes and microglia, play a role both in 
developmental myelination and in remyelination [211, 212]. However, differences 
between the regulation of development and regeneration of myelin do occur. OLIG1, for 
example, which is essential for developmental myelination, has a less redundant role 
during remyelination [213]. Another example is represented by the Notch signaling 
pathway, which is redundant during remyelination [214]. While remyelination can be 
quite efficient in experimental models, its efficiency remains generally low, leading to 
permanent deficits and dysfunctions. To a certain degree this decline is due to failure to 
the recruit OPC and to the failure of these cells to differentiate [187]. The underlying 
reasons for this are not completely understood but several pieces of evidence suggest the 
involvement of different factors, including age [215], gender [216], genetic background 
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[217], and also the presence of a variety of differentiation inhibitors that affect the glial 
regeneration potential [199, 218]. 
 
Myelin damage in multiple sclerosis 
Several neurological diseases are characterized by loss of myelin sheath and destruction 
of oligodendrocytes. As previously stated, primary demyelination in the CNS can be 
caused by genetic abnormalities affecting glial cells. The diseases associated with this 
kind of abnormalities, though rare, usually present during childhood with generalized 
neurological symptoms. They can be divided into those due to defects of lysosomal 
function, like metachromatic leukodystrophy, those resulting from defects in astrocytes 
providing trophic support for myelinating cells, like Alexander’s disease, and those due 
to deficiencies or misfolding of myelin proteins which in turn lead to abnormal 
myelinogenesis, like hypomyelinating leukodystrophies [219]. Primary CNS 
demyelination can also be caused by inflammation damage. The diseases associated with 
this kind of damage, characterized by myelin loss that occurs on a background of 
inflammation, include pathologies such as multiple sclerosis (MS), Marburg disease, 
neuromyelitis optica (NMO), Balo’s concentric sclerosis, acute disseminated 
encephalomyelitis (ADEM) and its hyperacute variant, acute hemorrhagic 
leukoencephalitis (AHL) [220].  
Among these, MS has been considered the lead disease featuring demyelination as a result 
of the scientific effort invested into its description and of its high prevalence.  
 
Multiple sclerosis is the most common cause of non traumatic disability in young people, 
with an onset usually between 20-40 years of age [221], affecting 2.5 million people 
throughout the world [222]. MS is characterized by inflammation, progressive 
demyelination and gliosis, axonal injury and loss. The pathological hallmarks of all the 
subtypes of this disease are focal areas, called plaques, of demyelination in the CNS, with 
surrounding inflammation and neurodegeneration [223, 224]. MS etiology however 
remains to be defined. Currently the most widely accepted hypothesis concerning MS 
pathogenesis is the autoimmune hypothesis. This hypothesis proposes autoimmune 
inflammation as the cause of demyelination, and auto-reactive leukocytes as disease 
initiators. The process begins when naïve myelin specific CD4+ T cells are primed in the 
lymph nodes by dendritic cells presenting either myelin or myelin cross-reactive epitopes. 
These cells differentiate into Th17 cells following stimulation by interleukin 23 (IL-23), 
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likely to play a central role in CNS autoimmunity [225, 226]. As these cells enter the CNS 
via subarachnoid space (SAS), together with activated macrophages, microglia and 
astrocytes, they secrete cytotoxic cytokines leading to demyelination [227-229]. A second 
hypothesis regarding MS onset is that the disease might be triggered by viral infection. 
This hypothesis does not exclude the autoimmune hypothesis, considering that virus 
could trigger the autoimmunity. Moreover, the viral infection might occur several years 
before the development of the MS lesions [230, 231]. A large amount of evidence 
supporting these hypothesis however was obtained using the most frequently used MS 
animal model, experimental autoimmune encephalomyelitis (EAE) and, while there are 
similarities between EAE and MS, there are still major differences between the two [232]. 
Therefore, EAE, while useful and suitable to study CNS-immune relationships and to test 
drugs targeting the CNS, might not represent a complete model of MS and the 
autoimmune hypothesis remains unproven.  
There is, however, a third hypothesis, defined as the oligodendrogliopathy hypothesis, 
which is based on neuropathological studies on MS. Through histopathological 
examination of MS lesions Lucchinetti et al. defined four major immunopatterns, on the 
basis of specific myelin protein loss, plaque extent and topography, immunoglobulin 
deposition, oligodendrocyte destruction, and complement activation [220, 233], each 
possibly reflecting a different pathogenesis. Whereas in the first two types, type 1 (T cell-
mediated autoimmune encephalomyelitis) and type 2 (T cell plus antibody-mediated 
autoimmune encephalomyelitis), demyelinated lesions are associated with inflammation 
consisting mainly of T cells and macrophages, in the other two types, type 3 (primary 
oligodendroglial apoptosis) and type 4 (primary oligodendroglial dystrophy), 
oligodendroglial death is a prominent feature in active and inactive lesions. The four types 
of patterns identified by Lucchinetti were further analyzed first by Barnett and Prineas 
[234] and later on by Henderson[235]. These studies, based on a thorough analysis of  
oligodendroglial apoptosis and inflammatory cell distribution in the various lesions, 
provided evidence suggesting that oligodendrocyte death and microglial activation are 
the initial event in MS lesion formation, followed by immune responses to scavenge dead 
myelin. Moreover, these immune responses seem to be permissive for oligodendroglial 
regeneration and remyelination, consistently with the observation that removal of myelin 
debris is necessary for remyelination [208]. The pathological heterogeneity observed in 
the four patterns is reflected in the clinical spectrum of MS. MS extends from an 
asymptomatic phase, of unknown duration starting at an unknown age, to clinically 
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symptomatic phases commonly known as radiologically isolated syndrome, clinically 
isolated syndrome (CIS), single-attack MS (SAMS), relapsing–remitting MS (RRMS), 
single-attack progressive MS (SAPMS), secondary progressive MS (SPMS), and primary 
progressive MS (PPMS) [220]. These different phases of MS are characterized by an 
interplay between different levels of inflammation-demyelination, remyelination and 
axonal loss [236]. Moreover, remission of the disease symptoms in the initial stages is 
most likely due to a combination of resolution of inflammation, axonal plasticity, and 
remyelination. Furthermore, in early MS lesions remyelination is a frequent phenomenon 
while the majority of chronic MS lesions is characterized by limited remyelination [237]. 
The efficiency of this remyelination process seems to be influenced by factors such as 
anatomical localization, disease course, lesion size, and other patient dependent factors 
[237-240]. Astrocytes also seem to play a role. Following injury, these cells are activated 
and form a glial scar, composed of a dense network of hypertrophic cells, whose 
formation is crucial for restoring the blood brain barrier (BBB) normal function and 
integrity. In demyelinating conditions, however, the glial scar also represents a physical 
barrier hindering OPC entry into the demyelinated area to interact with neurons [177, 
241-243]. Moreover, the scar also poses a biochemical obstacle for remyelination. The 
reactive astrocytes have marked changes in the expression levels of several molecules, 
including adhesion molecules, antigen presentation molecules, growth factors, receptor, 
cytokines, and protease inhibitors able to modify the composition of the extracellular 
matrix and to directly affect remyelination [244]. 
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Figure 8. Clinical course of multiple sclerosis. The majority of MS patients initially 
develop RRMS and, usually, during the remittance there is a spontaneous neurological 
recovery. Later, these patients progress to SPMS, and the functional recovery is abolished. 
The hallmark of MS lesions is inflammatory demyelination. Loss of mature oligodendrocytes 
is often associated with this demyelinating process. Adapted from Nakahara et al, 2012 
[229]. 
 
Whether the immune response is the cause of the pathogenesis or simply a consequence 
of the oligodendroglial cell death, the failure of the immune system to discriminate myelin 
components from foreign antigens plays a critical role in the pathophysiology of MS. 
Several CNS myelin proteins, including MBP, PLP, MAG and MOG, have been 
described as targets for autoantibodies in MS [245-251]. Recent evidence however also 
suggests possible roles for myelin lipids in MS. In fact, in MS patients increased serum 
levels of glycolipids and anti glycolipid antibodies have been reported [252-256]. For 
example, it has been hypothesized that anti GD1a antibodies, increased in sera of MS 
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patients, could have a role in the impairment of OPC maturation [257]. Moreover, it has 
been observed that MS patients exhibit an enhanced antibody response against sulfatides 
[258, 259]. Furthermore, recent evidence has shown that increased levels of serum and 
CSF sulfatides are found in MS patients and in their healthy siblings, with stage-specific 
accumulation of different molecular species [260-262], suggesting that the presence of 
sulfatide in these biological fluids could represent a risk/prognostic factor for the onset 
and progression of MS.  
Studies have also shown how anti-sulfatide antibodies can interact with the surface of 
cultured oligodendrocytes and affect the lateral organization of sulfatide with myelin 
proteins with opposite consequences (demyelination versus stimulation of myelin 
formation), depending on the type of ECM protein prevalent in the culture environment 
[167]. Hence, these antibodies might play a role in the onset of the disease, but they might 
also represent an important immunological tool for the treatment of demyelinating 
diseases [263]. 
 
Therapeutic approaches and remyelination promotion 
The adult mammalian CNS is usually regarded as a regeneration incompetent organ, as 
opposed to the PNS, where axonal connections and myelin sheaths can be restored more 
easily [264]. The development of therapies aimed to promote remyelination within the 
demyelinated lesion in the CNS is an important therapeutic goal. In MS, naturally 
occurring remyelination is an overall inefficient process that fails to successfully 
counteract the accumulation of lasting axonal damage and increasing brain atrophy, thus 
resulting in motor and neurological deficits [265, 266]. Considering OPCs have been 
detected in chronic MS lesions [267], other determinants such as factors affecting 
migration and differentiation of these cells might be involved in the failure to remyelinate. 
Treatment able to modulate these factors could be clinically valuable. One of the FDA 
approved immunomodulatory drugs for MS, Fingolimod, is a sphingosine-1-phosphate 
(S1P) receptor modulator able to control lymphocyte trafficking [268]. However, it was 
also found to modulate resident glial cells, including oligodendrocytes, and to increase 
remyelination efficiency [269-272]. It is however still unclear whether this remyelination-
promoting effect is simply due to a modulation of the inflammatory microenvironment or 
if it is due to a direct modulation of oligodendrocytes. Currently two major approaches 
involving a more direct stimulation of the remyelination process are being tested in animal 
models of demyelination. The first approach involves the transplantation of cells capable 
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of remyelination and is based on the evidence, gathered from multiple studies, that 
transplanted glial cells myelinate in the CNS following their introduction in the 
developing CNS of rodents with myelin mutations or with toxin-induced demyelination 
[273,274]. This approach however has limitations. There is little benefit to be gained by 
transplanting OPCs into lesions that already contain abundant cells with the ability to 
generate new oligodendrocyte. In these lesions the environment is inhibiting 
differentiation and regeneration and it would likely do the same for the exogenous cells. 
Moreover, the method of delivery also represents a problem. In fact, while for focal 
lesions a single injection might be enough, for diffuse disease multiple injections at 
different sites, each carrying a risk of intracerebral hemorrhage, would be necessary 
[275]. The second approach being tested in animal models of demyelination involves the 
promotion of repair by the resident stem- and precursor-cell populations in the adult CNS, 
through the administration of growth, trophic, and neuroprotective factors [276]. This 
approach is based on the idea that if the mechanisms of remyelination can be understood, 
and non-redundant pathways described, the causes of remyelination failure and 
consequently possible therapeutic targets, will be identified. As discussed in previous 
sections, remyelination failure is likely associated with either failed recruitment or 
differentiation of OPCs. However, different and mutually exclusive biologies underlie 
these two phases or remyelination. For example, PDGF promotes OPCs proliferation and 
migration but there is also evidence showing its inhibitory effect in the final stages of 
differentiation when the myelin sheath is formed [277]. Therefore, therapies aimed to 
recruit OPCs might not promote remyelination in situations where the main problem is 
OPC differentiation, and vice versa [278, 279]. 
An alternative therapeutic approach is the use of CNS reactive antibodies to promote 
remyelination [280]. So far, all identified remyelination promoting antibodies have 
natural autoreactive antibodies (NAbs) features and are of the IgM isotype, with one 
exception. This exception is represented by the high affinity anti-LINGO IgG antibodies, 
which are able to promote remyelination but do not have NAb features. One of these anti-
LINGO antibodies, BIIB033, a monoclonal antibody, is currently being tested for its 
efficiency as a remyelinating drug. Neutralization of LINGO-1, an axonal protein 
involved in the regulation of axonal growth and in OPC differentiation, has been found 
to promote remyelination in several animal models [281], and has fueled high 
expectations regarding its potential effect in MS. While a study investigating the effect 
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of BIIB033 in optic neuritis (ClinicalTrial.gov: NCT01721161) has not reached its 
endpoint, a Phase II study in RRMS is still underway (ClinicalTrial.gov: NCT01864148).  
Excluding the anti-LINGO IgGs, all remyelination promoting antibodies have NAbs 
features and are of the IgM isotype. These antibodies react to self antigens and, compared 
to conventional antibodies, they have a relatively low affinity. In addition, all 
remyelination promoting antibodies with identified antigens are polyreactive, as a result 
of their flexible antigen-binding site. Several of these monoclonal antibodies (mAbs) 
recognize not only protein antigens but also multiple sphingolipids. For example, the 
ganglioside-binding antibody A2B5 is able to recognize several GSLs due to their similar 
carbohydrate epitope [282, 283]. O4 recognizes sulfatide, seminolipid and also the 
unknown proligodendroblast antigen (POA) [284, 285], while HNK-1 targets MAG and 
also 3-sulfoglucuronyl paragloboside (SGPG) [286, 287]. All remyelination promoting 
IgMs produce a calcium influx in astrocytes, oligodendrocytes precursor cells, and 
immature oligodendrocytes [288]. The α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid glutamate receptor has been shown to mediate the calcium influx 
into oligodendrocytes (both OPC and immature OL), while this influx, after antibody 
stimulation, in astrocytes is mediated by inositol triphosphate-sensitive channels[288]. 
Another feature common to all remyelination promoting IgMs is their ability to access 
demyelinated lesions within the CNS. Direct evidence of this was obtained through a 
magnetic resonance imaging-based study, however, accumulation seems to occur only in 
models in which the BBB integrity is compromised, and not in animals without 
demyelination [289]. 
 
One of these remyelination promoting IgMs, recombinant human IgM22 (rHIgM22), is 
able to bind to myelin and to the surface of oligodendrocytes in vitro and has successfully 
completed a phase I clinical trial, aimed to evaluate safety, tolerability, pharmacokinetics 
and immunogenicity of a single intravenous dose of rHIgM22 in patients with MS 
(ClinicalTrial.gov: NCT01803867). In addition, a second phase I trial aimed to evaluate 
safety and tolerability in relapsing MS patients is now recruiting (ClinicalTrial.gov: 
NCT02398461). This antibody was first identified through the screening of human serum 
of a patient with Waldenström macroglobulinemia, a rare, low grade malignancy, 
characterized by the presence of IgM-secreting clonal cells in the bone marrow [290]. 
The serum of this patient was screened to identify antibodies able to bind to myelin, and, 
out of the six antibodies satisfying this criteria, two IgMs (sHIgM22 and sHIgM46) 
38 
 
promoted significant remyelination in vivo [291]. sHIgM22, in particular, was able to 
bind to the surface of rat, mouse, and human oligodendrocytes [291, 263]. Further 
characterization of sHIgM22 led to the production of its recombinantly expressed version, 
rHIgM22 [292], which was found able to promote myelin repair in Theiler’s virus 
infection-induced (TMEV) and lysolecithin-demyelinated models of multiple sclerosis 
[293]. The actual target and mechanisms of rHIgM22 are still under investigation 
however several pieces of evidence suggest that the antigen recognized by this antibody 
might be a plasma membrane lipid, possibly sulfatide, and that lipid raft might be 
involved in the signaling associated with rHIgM22 remyelinating activity. This 
hypothesis is based on the observation that the well known anti-sulfatide antibody O4 and 
rHIgM22 have a similar binding pattern to CNS tissues [294], and that binding of 
rHIgM22 is abolished in CNS tissue sections from CST (-/-) mice [295]. Moreover, 
existing literature suggests that the binding target of rHIgM22 could be associated with 
detergent-resistant membranes (DRM)/lipid rafts and that rHIgM22 biological activity 
depends on lipid raft organization[294, 295]. rHIgM22 exerts its biological activity by 
inhibiting apoptotic signaling in OPCs and also by inhibiting the differentiation of these 
cells [294, 296]. The inhibition of the apoptotic signaling pathways is achieved via 
reduction of caspase-3 and caspase-9 cleavage and alteration of the caspase gene 
expressions in TMEV mice and in primary rat oligodendrocytes [294, 296], and this is 
dependent on calcium influx, through CNQX-sensitive AMPA channels [294]. Moreover, 
literature strongly suggests that rHIgM22 biological activity, responsible for its myelin-
repair promoting activity, could require a multimolecular complex organizing Lyn and 
the cell surface molecules integrin αvβ3 and PDGFRα[296, 297]. Taken together, these 
observations have led to hypothesize that rHIgM22, through its pentameric structure, 
could mediate the clustering of a lipid antigen and stabilize lipid rafts domains. Moreover, 
it could determine the reorganization of Lyn, integrin αvβ3 and PDGFRα to form a 
signaling complex which, in turn, promotes OPC survival and proliferation [295, 296]. 
Signaling through this complex determines Lyn activation, and subsequent activation of 
the ERK 1/2 MAPK cascade, leading to the inhibition of caspase-3/9, to inhibition of 
OPCs differentiation and promotion of OPCs proliferation [297, 298].  
In isolated OPCs, PDGF is required for rHIgM22-mediated inhibition of apoptotic 
signaling and differentiation. PDGF is produced by neurons and astrocytes and stimulates 
OPC proliferation and promotes OPC survival both in vivo and in vitro. Indeed, IgM-
mediated OPC proliferation is detectable only in cultures containing substantial amounts 
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of astrocytes, microglia and OPCs (mixed glial cultures) but not in highly enriched OPC 
population[297]. 
 
 
 
Figure 9. Proposed mechanism of action of rHIgM22. Binding of rHIgM22 to the surface 
of oligodendrocyte determines a reorganization of the membrane, favoring the interaction of 
Lyn, integrin αvβ3 and PDGFαR. IgM-stimulated activation of Lyn, with consequent 
activation of ERK 1/2 determines the inhibition of the apoptotic pathway and of OPC 
differentiation. Other factors (e.g. PDGF) might be required to promote the proliferation of 
these cells. Adapted from Watzlawik et al, 2013 [298]. 
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AIM OF THE STUDY 
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A number of CNS diseases are characterized by the damage or loss of myelin and 
oligodendrocytes, leading to demyelination. This pathological process is typically a 
consequence of either a direct insult aimed at the oligodendrocytes, or of primary axonal 
loss, and ultimately leads to the loss of the myelin sheath. Following demyelination in the 
central nervous system, a demyelinated axon has two possible fates. The normal response 
to demyelination, at least in most experimental models, is spontaneous remyelination, a 
process mediated by oligodendrocyte precursor cells. These cells are activated and 
recruited by the other glial cells in response to CNS injury and their proliferation and 
subsequent differentiation leads to the formation of new myelin sheaths, typically thinner 
and shorter than their developmental counterparts but nevertheless associated with 
functional improvement or recovery. However, even though in experimental models this 
process is efficient, remyelination is often inadequate in human demyelinating diseases 
such as multiple sclerosis. If remyelination fails, the axon, devoid of its myelin sheath, 
undergoes deep molecular reorganization and physiological changes that ultimately result 
in axonal dysfunction, degeneration, and loss of sensory and motor function [188]. For 
this reason, therapies that increase the chances of the regenerative outcome of 
demyelination are keenly sought. 
One of the therapeutic approaches that is currently being developed to improve the 
regenerative outcome involves the use of CNS reactive antibodies to promote 
remyelination [280]. One of these antibodies, rHIgM22, which is able to bind to myelin 
and to the surface of oligodendrocytes in vitro, has successfully completed a phase I 
clinical trial for the treatment of MS (ClinicalTrial.gov: NCT01803867). Moreover, a 
second phase I trial aimed to evaluate safety and tolerability in relapsing MS patients is 
now recruiting (ClinicalTrial.gov: NCT02398461). This antibody is able to enter the 
CNS, accumulate at lesion site and promote remyelination in mouse models of chronical 
demyelination [289, 291]. The antigen recognized by this antibody and the molecular 
mechanism underlying the remyelinating activity of rHIgM22 however are yet to be 
elucidated. Evidence suggests that the binding target of rHIgM22 could be associated 
with plasma membrane lipid rafts, and that lipid rafts might be involved in the signaling 
associated with the biological activity of this antibody [294, 295]. Moreover, a signaling 
complex in OPCs responsible for rHIgM22-mediated actions including platelet-derived 
growth factor (PDGF)Rα, integrin αvβ3 and the Src family kinases (SFK) Lyn has been 
identified [295, 296]. Despite this finding, isolated OPCs do not respond to rHIgM22 
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treatment, instead mixed glial cultures consisting of astrocytes, OPCs and microglial cells 
demonstrate observable rHIgM22-mediated OPC proliferation [299]. 
In the light of previous statements, the aim of this study is to analyze the plasma 
membrane lipid rafts composition in MGC and the effects exerted by rHIgM22 on these 
cells after single dose treatment of various duration. The characterization of the 
membrane microenvironment necessary for the activity of this antibody, able to promote 
remyelination in validated mouse models of MS, and the analysis of alteration induced 
by its action could contribute to understand the signaling mechanisms underlying the 
biological activity of rHIgM22. Moreover, this could allow to understand the molecular 
mechanisms involved in the MS and to define new potential therapeutic targets.  
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Materials  
Commercial chemicals were the purest available and, unless otherwise stated, were 
purchased from Sigma Aldrich Srl. 
Ca2+ and Mg2+-free HBSS, D-Glucose, BSA fraction V, HEPES, trypsin, sodium 
pyruvate, poly-D-lysine, PBS, Na3VO4, KCl, NaOH, methanol, chloroform, hexane, 
NaCl, PMSF, aprotinin, sucrose, and EDTA were purchased by Sigma Aldrich; 
penicillin/streptomycin, bovine fetal serum, DMEM high glucose, and glutamine from 
Euroclone Spa; MgSO4, CaCl2, and HPTLC plates from Merck; DNaseI from Roche Spa; 
acetic acid from Fluka; HCl from VWR International PBI Srl. 
 
Chrompure Human IgM (#009-000-012) has been purchased from Jackson Immuno 
Research, Inc.; Human purified IgM (#I8260) and anti-GAPDH (#G9545) were 
purchased from Sigma Aldrich; anti-Integrin αv (#611012) was purchased from Becton, 
Dickinson and Company; anti-Akt (#9272), anti-Caveolin 1(#3267), anti-P-
Src(Y416)family (#2101), anti-PDGFRα (#3164) and anti-Lyn (#2732) were purchased 
from Cell Signaling Technology; anti-PrP(SAF32)(#189710) was purchased from 
Cayman Chemical. 
HRP-conjugated anti-mouse IgG antibody (#31430) has been purchased from Thermo 
Fisher Scientific, Inc.; HRP-conjugated anti-rabbit IgG antibody (#7074) was purchased 
from Cell Signaling Technology. 
The rHIgM22 antibody has been kindly provided by Acorda Therapeutics, Inc. (Ardsley, 
NY). 
 
Pure galactosylceramide (GalCer), and sulfatides were purchased from Avanti Polar 
Lipids; phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol 
(PI), phosphatidylserine (PS), sphingomyelin (SM), and phosphatidic acid (PA) were 
purchased from Sigma Aldrich. Lysosulfatide was purchased from Matreya. Ceramide, 
gangliosides (GM3, GM2, GM1, GD3, GD1a, GD1b, GT1b), glucosylceramide (GlcCer), 
and lactosylceramide (LacCer) were synthesized or purified in our laboratories.  
 
Animal specimens 
For the experiments reported in this thesis, the sources of animal specimens were wild 
type (WT) C57BL/6N mice, used for preparation of mixed glial cultures. 
 
45 
 
Cell culture 
 
Mixed glial cell (MGC) culture 
A primary mixed glial culture, composed of astrocytes, oligodendrocytes, and microglia, 
is obtained when newborn disaggregated cerebral brain cells from rat or mouse are plated 
at high cell density in serum-supplemented medium [297, 300]. In this culture model, 
neurons fail to survive and, after one week, mixed glial cell cultures are free of neurons, 
meningeal cells, and fibroblasts. MGC cultures were prepared according to Watzlawik et 
al [297]. Briefly, the hemispheres from P3 mice brains were minced with a surgical blade 
and then incubated for 30’ at 37°C in 0.05% trypsin in modified HBSS (Ca2+ and Mg2+ 
free HBSS containing 5 g/L D-glucose, 3 g/L BSA fraction V, 20 mM HEPES, 100 U/mL 
penicillin and 100 μg/mL streptomycin). Following the addition of MgSO4 and DNase I, 
the sample was centrifuged at 200 g at 8°C for 5 minutes and resuspended in modified 
HBSS. The tissue was then further dissociated by trituration through a sterile flame 
narrowed glass pipette, centrifuged at 200 g at 8°C for 10 minutes, resuspended in culture 
medium and plated on Petri dishes or T75 flasks coated with poly-D-lysine (25 μg/mL). 
The cells were cultured in DMEM high glucose containing 10% heat inactivated FBS, 
100 U/mL penicillin, 100 μg/mL streptomycin, 1 mM sodium pyruvate, and 2 mM 
glutamine and the culture medium is changed every 3/4 days.  
With this protocol it is possible to obtain cultures with about 60-70% of astrocytes, 30-
40% of OPCs, and less than 3% of microglial cells. 
 
Treatment of cell cultures with [1-3H]sphingosine  
24 h after seeding, cells were incubated in the presence of  3.68 × 10-8 M [1-
3H]sphingosine [1-3H]sphingosine (5 ml/dish) in culture medium for 2 h (pulse). After 
the pulse, the medium was replaced with fresh medium without radioactive sphingosine, 
and cells were further incubated for up to 48 hours (chase). Under these conditions, all 
sphingolipids (including ceramide, SM, neutral glycolipids, and gangliosides) and 
phospholipids (obtained by recycling of radioactive ethanolamine formed in the 
catabolism of [1-3H]sphingosine) were metabolically radiolabeled. 
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Preparation of DRM fractions by sucrose gradient centrifugation 
Cells were subjected to homogenization and to ultracentrifugation on discontinuous 
sucrose gradient, as previously described [301]. Briefly, cells were harvested, lysed in 1% 
Triton X-100 in TNEV (10 mM Tris-HCl buffer, pH 7.5, 150 mM NaCl, 5 mM EDTA) 
in the presence of 1 mM Na3VO4, 1 mM PMSF, and 75 mU/ml aprotinin, and Dounce 
homogenized (10 strokes, tight). Cell lysate was centrifuged for 5 min at 1300 g to remove 
nuclei and cellular debris. The postnuclear supernatant (PNS) was mixed with an equal 
volume of 85% sucrose (w/v) in TNEV, placed at the bottom of a discontinuous sucrose 
gradient (30% - 5%), and centrifuged for 17 h at 200,000 g at 4°C with ultra-centrifuge 
Beckman Coulter optima L-90K. After ultracentrifugation, eleven fractions were 
collected starting from the top of the tube. The entire procedure was performed at 0-4°C 
in ice immersion. The protein levels and lipid distribution were analyzed individually in 
each fraction. A part of each fraction (about 50%) was subjected to dialysis, with the end 
to eliminate the excess of sucrose due to the fractioning process, snap frozen and 
lyophilized. The other part of each fractions was directly mixed with Laemmli buffer (1x: 
62.5 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 0.01% Bromophenol blue, 
10% glycerol) for protein analysis, as described further. To investigate the metabolism of 
sphingolipids and phospholipids, cells were previously labeled with [1-3H]sphingosine.  
 
 Lipid analysis 
 
Sample preparation 
Cultured mouse mixed glial cells were collected after washing the flasks and/or petri 
dishes twice with PBS containing 1 mM Na3VO4. The cells were scraped twice in PBS 
containing 1 mM Na3VO4 and centrifuged at 3000 rpm, 4°C for 5 minutes. The 
supernatant was discarded, the pellet was snap frozen and stored at -80°C. Frozen samples 
were then thawed at room temperature (RT), resuspended in ice-cold water, snap frozen 
and lyophilized. 
 
Total lipid extraction, phase partitioning and alkali treatment 
Lipids from the lyophilized samples were extracted with chloroform/methanol/water 
20:10:1 (v/v/v) and subjected to a modified two-phase Folch’s partitioning to obtain the 
aqueous (Aq. Ph.) and the organic phases (Or. Ph.) [4]. Briefly, 1550 μL of the solvent 
system were added to the lyophilized samples. The samples were then mixed at 1100 rpm, 
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RT for 15 minutes and centrifuged at 13200 rpm, RT for 15 minutes. The supernatant was 
collected as Total lipid extract (TLE) and the extraction was repeated again twice by 
adding the 1550 μL of the solvent system to the pellets. The pellets were air dried and 
resuspended in 1N NaOH and incubated overnight at RT before being with water to 0.05N 
NaOH to allow the determination of the protein content with DC assay. Aliquots of the 
TLE were then subjected to phase partitioning adding 20% of water by volume. The 
samples were then mixed at 1100 rpm, RT for 15 minutes and centrifuged at 13200 rpm, 
RT for 15 minutes. The Aq. Ph. were recovered, and CH3OH:H2O 1:1 (v/v) was added to 
the organic phase before mixing the samples at 1100 rpm, RT for 15 minutes and 
centrifuging at 13200 rpm, RT for 15 minutes. The new aqueous phases were recovered 
and united to the ones previously collected. The aqueous phases were dried under N2 flux, 
and resuspended in water before undergoing dialysis and lyophilization. The organic 
phases were dried under N2 flux and resupended in a known volume of 
cholesterol/methanol 2:1. Aliquots of the organic phases were then subjected to alkali 
treatment to remove glycerophospholipids [302]. 
 
Thin layer chromatography 
To determine lipid content, the various samples were analyzed by mono-dimensional 
silica gel HPTLC using different solvent systems. The total lipid extracts were analyzed 
using chloroform/methanol/0.2% aqueous 60:35:8 (v/v/v) as a solvent system, the 
aqueous phases were analyzed with chloroform/methanol/0.2% aqueous CaCl2 50:42:11 
(v/v/v), whereas the organic phases and the methanolyzed organic phases were analyzed 
using chloroform/methanol/water 110:40:6 (v/v/v). The organic phases were also 
subjected to HPTLC separation with chloroform/methanol/acetic acid/water 30:20:2:1 
(v/v/v/v) to analyze the glycerophospholipid content. After separation, radioactive lipids 
were detected and quantified by radioactivity imaging performed with a Beta-Imager 
2000 instrument (Biospace Lab, Paris, France) using an acquisition time of about 48 h. 
The radioactivity associated with individual lipids was determined with the specific 
M3Vision software provided by Biospace Lab. Identification of lipids after separation 
was assessed by co-migration with lipid standards. Cholesterol was separated by 
monodimensional HPTLC using the solvent system Hexane/Hetyl Acetate 3:2 (v/v) and 
visualized by spraying the plate with 15% solution of  concentrated sulfuric acid in 1-
butanol. 
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Protein analysis 
 
Protein quantification 
The protein quantification was performed through DC assay (Bio-Rad). The assay was 
performed in 96 well plates following the protocol supplied with the Bio-Rad DC assay 
kit. The samples were analyzed in triple, like the protein standard, bovine serum albumin 
(BSA), at different concentrations. 25 μL of reagent A and 200 μL of reagent B, both 
supplied with the kit, were added to each well. After 15 minutes of incubation, the 
absorbance at 750 nm was measured with the spectrophotometer. The samples reading 
were compared with the ones of the standard. The assay is linear between 1.5 and 7.5 μg 
of protein amount. 
 
Electrophoresis and Western Blotting 
The samples were analyzed using electrophoresis on a polyacrilamide gel with denaturing 
conditions. The samples were resuspended in Laemmli buffer (1x: 62.5 mM Tris-HCl pH 
6.8, 2% SDS, 5% 2-mercaptoethanol, 0.01% Bromophenol blue, 10% glycerol) and 
boiled for 5 minutes at 100°C before being analyzed. 
The electrophoresis run was performed using a Miniprotean II unit, produced by Bio-Rad. 
To obtain optimal resolution, a stacking gel is polymerized on top of the resolving gel. A 
solution of 25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3 was used as running buffer. 
The proteins were separated using 10% polyacrylamide gels. 
After electrophoresis separation, proteins were transferred to polyvinylidene difluoride 
(PVDF) membranes (Immobilion P-Membrane #IPVH00005 Merkck Millipore), at 200 
mA for 3 hours at 4°C with a wet blotting (Mini Transblot Biorad). The transfer buffer 
used is Blotting buffer 1x (25 mM Tris-HCl, 192 mM glycine, 15 % methanol, pH 8.0-
8.5). 
After the transfer, the PVDF membranes were immunoblotted using Integrin αv, Akt, 
Caveolin 1, Lyn, PDGFRα, GAPDH, P-Src(Y426) family and PrP(SAF32). Briefly, after 
the transfer the membrane was incubated in 5% milk in TBS-T 0.05% (1 mM Tris-HCl 
pH 8, 150 mM NaCl, 0.05% Tween) to block the non-specific binding sites of the 
membrane. The membrane was then washed three times with TBS-T 0.05% and incubated 
with a specific antibody (primary antibody) for time depending on the antibody used. The 
primary antibody was diluted in a solution of TBS-T 0.05% containing 1% bovine serum 
albumin (BSA). The membrane was washed again with TBS-T 0.05% for four times, to 
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get rid of the antibody excess, before being incubated with the secondary antibody 
conjugated with horseradish peroxidase (HRP) at room temperature for 45 minutes. For 
membranes previously incubated with either Integrin αv or PrP(SAF32) primary 
antibodies, an anti-mouse IgG (Thermo, #31430) was used. For membranes incubated 
with Akt, Caveolin 1, PDGFRα, GAPDH and P-Src(Y416) family and Lyn antibodies, an 
anti rabbitIgG-HRP (Cell Signaling, #7074) was used. The membrane was then washed 
again for six times and the peroxidase activity was assessed through incubation with a 
non-radioactive light emitting substrate for the detection of immobilized specific antigens 
conjugated with horseradish peroxidase-linked antibodies (LiteAbLot Plus, Euroclone) 
for 2 minutes. The luminescent compound generated following the reaction can be 
detected through exposition to the Alliance 9.7 Western Blot Imaging System fom UVItec 
Limited and analyzed by the Alliance 1D software. 
 
Treatment of MGC cultures with rHIgM22 
 
Treatment with rHIgM22 and Human IgMs 
After 24 hours from the beginning of the chase, MGC, labeled with [1-3H]sphingosine, 
were  incubated in the presence of a MGC complete medium, described above, added 
with 10μg/mL of either rHIgM22 (lot 1-FIN-1223), Human IgM, Human IgM directly in 
the petri dishes. The morphological effect of this treatment was evaluated at different time 
(6, 24 and 48 hours) after treatment by observation at the inverted fluorescence microscope 
(IX50 Olympus).  
The following experiments were conducted after the treatment. 
 
ASMase activity assay 
 
Sample preparation  
MGC after 6, 24 and 48h of treatment with rHIgM22 (lot 1-FIN-1223), Human IgM 
(Jackson #009-000-012) and Human IgM (Sigma #I8260), have been washed twice and 
scraped twice in PBS containing 1 mM Na3VO4. Then, cells were centrifuged at 3000 
rpm for 10 minutes at 4°C, the supernatant was discarded and pellet was resuspended in 
100 μL 0.2% Triton X-100 in H2O. After 10 minutes on ice, samples were sonicated (3 
times; 10 second “on”, 30 second “off”) and the protein content was determined using 
DC assay. Each sample was, then, diluted to obtain a concentration of 1 µg/µL. 
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Substrate preparation 
500 pmol of SM have been mixed with 10000 dpm (about 12 pmol) of  3H-SM and added 
with 25 μL of 0.2% Triton X-100 in CHCl3:CH3OH 2:1 (v/v) for each sample to analyze. 
The mixture obtained was vortexed, sonicated (3 times; 10 second “on”, 30 second “off”) 
and dried under N2 flux. After, 25 μL of 250 mM sodium acetate, pH 5.1 for each sample 
were added. 
The substrated prepared has been mixed at 300 rpm, 37°C for 1h to allow micelles 
formation. 
  
ASMase activity reaction 
25 μg of protein of cell lysates were added to 25 μL of reaction substrate and samples 
(final SM concentration 10 μM) were incubated for 2 h at 37°C. The reaction was stopped 
by the addition of 200 μL of CHCl3:CH3OH 2:1 (v/v) at RT for 20 min, followed by 
centrifugation at 13200 rpm for 20 min. Organic and aqueous phases were, then, separated 
and the radioactivity associated with each phase was determined by liquid scintillation 
counting. For samples labelled as “Blank”, 25 μL of 0.2% Triton X-100 in H2O were 
added to the substrate instead of the cell lysate. Each reaction was run in triplicate. The 
amount of SM hydrolyzed was determined through autoradiography. 
 
Statistical analysis 
 
Experiments were run in triplicate, unless otherwise stated. Data are expressed as mean 
value ± SD and were analyzed by one-way analysis of variance followed by Student-
Neuman-Keul’s test.  p-values are indicated in the legend of each figure. 
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The actual target and mechanisms of rHIgM22 are still under investigation however 
existing literature suggests that the antigen recognized by rHIgM22 might be a plasma 
membrane lipid, possibly sulfatide, that the binding target of rHIgM22 could be 
associated with detergent-resistant membranes (DRM)/lipid rafts, and that rHIgM22 
biological activity depends on lipid raft organization [294, 295]. 
Moreover, Wootla et al., suggested an involvement of the astroglial growth factor PDGF 
in rHIgM22-mediated actions in OPCs; in fact they identified a signaling complex in 
OPCs responsible for rHIgM22-mediated actions including platelet-derived growth factor 
(PDGF)αR, integrin αvβ3 and the Src family kinases (SFK) Lyn113. Further, they 
observed that isolated OPCs do not respond to rHIgM22 treatment, instead mixed glial 
cultures consisting of astrocytes, OPCs and microglial cells demonstrate observable 
rHIgM22-mediated OPC proliferation [299]. 
Therefore, analysis of lipids and proteins distribution in MGC gradient fractions and the 
effect of rHIgM22 treatment on MGC were performed. 
 
Lipid distribution in MGC gradient fractions 
In order to investigate the possible target of rHIgM22 in plasma membrane lipid rafts, 
MGC gradient fractioning was performed. To do this, cells, previous labeled with              
[1-3H]sphingosine, were lysed in the presence of Triton X-100 and subjected to 
discontinuous sucrose gradient centrifugation as described in Materials and Methods 
section. To determine how lipids distributed in the various fractions, radioactivity 
associated with the single fractions was determined by liquid scintillation counting. 
The radioactivity distribution, as shown in in Figure 1, allowed to define three major 
fractions: a low density, detergent resistant membrane fraction (DRM, fractions 4 and 5), 
an intermediate fraction (INT., fractions 6, 7 and 8) and an high density fraction (HD, 
fractions 9, 10 and 11). 
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Figure 1. Radioactivity distribution in MGC gradient fractions. Cells were subjected to 
metabolic labeling with [1-3H]sphingosine,  homogenization and to ultracentrifugation on 
discontinuous sucrose gradient, as previously described in Materials and Methods section. Briefly, 
cells were harvested, lysed in 1% Triton X-100 in TNEV and Dounce homogenized. Cell lysate 
was centrifugated to remove nuclei and cellular debris and the postnuclear supernatant (PNS) was 
mixed with an equal volume of 85% sucrose (w/v) in TNEV, placed at the bottom of a 
discontinuous sucrose gradient (30% - 5%), and ultracentrifugated. Eleven fractions were collected 
starting from the top of the tube. Radioactivity distribution was analyzed individually in each 
fraction by liquid scintillation counting. 
 
TLC separations of lipid extracts from MGC gradient fractions 
In order to evaluate the lipid pattern of the different MGC gradient fractions , total lipids, 
have been extracted using chloroform/methanol/water 20:10:1 (v/v/v) and partitioned as 
described in Materials and Methods section. Then, TLC analysis of total lipids, organic 
and aqueous phases obtained were performed. 
Sphingomyelin (SM), phosphatidyletanolamine (PE) and gangliosides were the most 
represented lipids in the analyzed fractions, as shown in Figure 2. 
Lipid separation of the organic phases, performed using HPTLC, revealed the presence 
mainly of  SM, PE and ceramide (Cer) (Figure 3). In particular, SM was enriched in 
DRM fraction and decreased both in intermediate fraction and in HD fraction; PE, was 
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enriched in HD fraction and decreased both in intermediate fraction and in DRM fraction; 
and ceramide was present in all the fractions analyzed. 
Moreover, the analysis of the aqueous phases, reported in Figure 4, showed the presence 
of various gangliosides, namely GM1, GM2, GM3 GD3, GD1a and GT1b, which were 
found to be enriched in the DRM fraction. 
 
Summarizing, the data just described allowed to compare the distribution of different 
classes of lipids among the MGC gradient fractions. 
In details, sphingolipids (SL), including ceramide (Cer), glucosylceramide (GlcCer), 
sphingomyelin (SM) and gangliosides, were more represented in the DRM fraction and 
slightly represented in the HD fraction; differently, phospholipids (PL), including 
phosphatididylethanolamine (PE) and phosphatidic acid (PA), took an opposite 
distribution, as shown in Figure 5. 
Moreover, Figure 5 showed that both SM and gangliosides were distributed, mainly, in 
the DRM fraction and very poorly represented in the other fractions. So, as expected, the 
DRM fraction was highly enriched in sphingolipids, and relatively depleted of 
glycerophospholipids. The major amount of glycerophospholipids existed in HD fraction.  
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Figure 2.  TLC separation of total lipids extract from MGC gradient fractions. After 
metabolic labeling of MGC lipids with [1-3H]sphingosine, cell gradient fractions were prepared 
by sucrose gradient centrifugation after lysis in the presence of 1% Triton X-100 as described 
under “Materials and Methods”. The radioactive lipids extract were separated by HPTLC using 
chloroform/methanol/CaCl2 0.2% 60:35:8 by volume as solvent system, and the plates were 
acquired under Beta-Imager 2000 instrument. The radioactivity image was quantified with the 
specific M3Vision software provided by Biospace Lab. Right panel relative quantities of 
components present in each sucrose gradient fraction 4–11 as in the left panel. The relative 
quantities of each lipid in DRM (fractions 4-5), Intermediate (fractions 6-7-8) and HD (fractions 
9-10-11) fractions were calculated by densitometry and were expressed as percentage of total 
signal assessed in the histogram.  
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Figure 3.  TLC separation of organic phases obtained from MGC gradient fractions. After 
metabolic labeling of MGC lipids with [1-3H]sphingosine, cell gradient fractions were prepared 
by sucrose gradient centrifugation after lysis in the presence of 1% Triton X-100 as described 
under “Materials and Methods”. The lipids of different fractions were extracted with 
chloroform/methanol/water 20:10:1 by volume. The total lipid extract of different fractions were 
also subjected to a modified two-phase Folch’s and were divided into aqueous phase and organic 
phase. The radioactive lipids extract were separated by HPTLC using chloroform/methanol/water 
110:40:6 by volume as solvent system, and the plates were acquired under Beta-Imager 2000 
instrument. The radioactivity image was quantified with the specific M3Vision software provided 
by Biospace Lab. Right panel relative quantities of components present in each sucrose gradient 
fraction 4–11 as in the left panel. The relative quantities of each lipid in DRM (fractions 4-5), 
Intermediate (fractions 6-7-8) and HD (fractions 9-10-11) fractions were calculated by 
densitometry and were expressed as percentage of total signal assessed in the histogram 
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Figure 4.  TLC separation of aqueous phases obtaned from MGC gradient fractions. After 
metabolic labeling of MGC lipids with [1-3H]sphingosine, cell gradient fractions were prepared 
by sucrose gradient centrifugation after lysis in the presence of 1% Triton X-100 as described 
under “Materials and Methods”. The lipids of different fractions were extracted with 
chloroform/methanol/water 20:10:1 by volume. The total lipid extract of different fractions were 
also subjected to a modified two-phase Folch’s and were divided into aqueous phase and organic 
phase. The radioactive lipids extract were separated by HPTLC using chloroform/methanol/ CaCl2 
0.2% 50:42:11 by volume as solvent system, and the plates were acquired under Beta-Imager 2000 
instrument. The radioactivity image was quantified with the specific M3Vision software provided 
by Biospace Lab. Right panel relative quantities of components present in each sucrose gradient 
fraction 4–11 as in the left panel. The relative quantities of each lipid in DRM (fractions 4-5), 
Intermediate (fractions 6-7-8) and HD (fractions 9-10-11) fractions were calculated by 
densitometry and were expressed as percentage of total signal assessed in the histogram.  
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Figure 3. Lipid distribution in MGC gradient fractions. HPTLC analysis of total lipids extracts, 
aqueous and organic phases of [1-3H]sphingosine labeled MGC gradient fractions were performed. 
Panel A shows the sphingolipids and phospholipids distribution in the different fractions. Panel 
B shows the sphingomyelin (SM) distribution in the different fractions. Panel C shows the 
gangliosides distribution in the different fractions.  
 
Analysis of cholesterol content in MGC gradient fractions 
Sphingolipid-enriched domains, that are reported to be enriched in gangliosides, 
sphingomyelin, and cholesterol [301], are emerging as membrane compartments with 
relevant biological functions. The distribution of cholesterol in MGC fractions prepared 
by sucrose gradient centrifugation is shown in Figure 6. Unlike what was expected, in 
MGC cholesterol was more represented in the HD fraction than in DRM fraction. In fact, 
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about 50% of cellular cholesterol was associated with HD fraction and only about 25% 
of cellular cholesterol was associated with DRM fraction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Distribution of cholesterol in sucrose gradient fractions from MGC culture. The amount of 
cholesterol in gradient fractions was determined after organic phases separation by HPTLC using 
Hexane/Hetyl Acetate 3:2 (v/v), as solvent system and  visualized by sprying with 15% solution of  
concentrated sulfuric acid in 1-butanol (Panel A). Data are expressed as percentages of total cholesterol 
present in the total fractions (Panel B).   
 
Protein distribution in MGC gradient fractions 
Glycosphingolipids clusters at the cell surface membrane interact with functional 
membrane proteins such as integrins, growth factor receptors, tetraspanins, and 
nonreceptor cytoplasmic protein kinases to form "glycosynaptic domains" controlling cell 
growth, adhesion, and motility. 
Therefore, western blotting analysis were performed with the aim to verify the 
distribution in MGC gradient fractions of particular proteins of interest (Integrin αv, Lyn, 
Akt, Caveolin 1, PrP(SAF32)).  
To do so, half of each fraction obtained from MGC, prepared as described in Material and 
Methods section, was subjected to SDS PAGE followed by western blot analysis.  
In Figure 8 (Panel A) the distribution of Integrin αv among MGC gradient fractions was 
shown. Integrins are α/β heterodimeric cell surface receptors that play a pivotal role in 
cell adhesion and migration, as well as in growth and survival. Integrins not only transmit 
signals to cells in response to the extracellular environment (outside-in signaling), but 
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also sense intracellular cues to alter their interaction with the extracellular environment 
(inside-out signaling) [303, 304]. Integrin αv was localized in HD fraction. 
In Figure 7 (Panel A) the distribution of Lyn among MGC gradient fractions was shown. 
Lyn, one of the Src family members, is predominantly expressed in hematopoietic cells. 
Two tyrosine residues have been reported to play a crucial role in the regulation of protein 
tyrosine kinases of the Src family. Tyrosine phosphorylation and activation of Lyn occurs 
upon association with cell surface receptors [305]. Lyn was localized both in DRM and 
in HD fractions. 
In Figure 8 (Panel B) the distribution of Akt among MGC gradient fractions was shown. 
Akt plays a critical role in controlling survival and apoptosis [306-308]. This protein 
kinase is activated by insulin and various growth and survival factors to function in a 
wortmannin-sensitive pathway involving PI3 kinase [307, 308]. It is activated by 
phospholipid binding [309] and by phosphorylation within the carboxy terminus at 
Ser473 and promotes cell survival by inhibiting apoptosis through phosphorylation and 
inactivation of several targets. Akt was localized in HD fraction. 
In Figure 7 (Panel B) the distribution of Caveolin 1 among MGC gradient fractions was 
shown. Caveolins are the principal structural components of the cholesterol/sphingolipid-
enriched plasma membrane microdomain caveolae. Three members of the caveolin 
family (caveolin-1, -2, and -3) have been identified with different tissue distributions. 
Caveolins form hetero- and homo-oligomers that interact with cholesterol and other lipids 
[310]. Caveolins are involved in diverse biological functions, including vesicular 
trafficking, cholesterol homeostasis, cell adhesion, and apoptosis, and are also implicated 
in neurodegenerative disease [311]. Caveolins interact with multiple signaling molecules 
such as Gα subunit, tyrosine kinase receptors, PKCs, Src family tyrosine kinases, and 
eNOS [310, 311]. It is believed that caveolins serve as scaffolding proteins for the 
integration of signal transduction. Caveolin 1 was localized mainly in DRM fraction, but 
was also present in HD fraction.  
In Figure 7 (Panel C) the distribution of PrP(SAF32) among MGC gradient fractions 
was shown. Cellular prion protein (PrPC) is a highly conserved protease-sensitive 
sialoglycoprotein of unknown function which is endogenously expressed in brain. Studies 
have shown this protein to be anchored to the external surface of the cell membrane by 
glycosyl-phosphatidylinositol [312]. PrP(SAF32) was localized in DRM fraction.  
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Figure 7.  Analysis of different proteins expressed in DRM fraction. Half of each fraction 
analyzed was mixed with Laemmli buffer and boiled for 5 minutes before analysis. Electrophoresis 
separation was performed in a 10% polyacrylamide gel. After electrophoresis separation, proteins 
were transferred to PVDF membranes, subjected to immunoblotting using three different 
monoclonal primary antibody (Lyn (Panel A), Caveolin 1 (Panel B) and PrP(SAF32) (Panel C)) 
and incubated with the secondary antibody conjugated with HRP. The peroxidase activity was 
assessed through incubation with a non-radioactive light emitting substrate for the detection of 
immobilized specific antigens conjugated with HRP-linked antibodies and detected through 
exposition to the Western Blot Imaging System, as described in Material and Methods section.  
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Figure 8.  Analysis of different proteins in HD fraction. Half of each fraction analyzed was 
mixed with Laemmli buffer and boiled for 5 minutes before analysis. Electrophoresis separation 
was performed in a 10% polyacrylamide gel. After electrophoresis separation, proteins were 
transferred to PVDF membranes, subjected to immunoblotting using two different monoclonal 
primary antibody (Integrin αv (Panel A) and  Akt (Panel B)) and incubated with the secondary 
antibody conjugated with HRP. The peroxidase activity was assessed through incubation with a 
non-radioactive light emitting substrate for the detection of immobilized specific antigens 
conjugated with HRP-linked antibodies and detected through exposition to the Western Blot 
Imaging System, as described in Material and Methods section.. 
 
Effect of rHIgM22 on MGC 
In order to investigate the possible role of rHIgM22, the effect of rHIgM22 on MGC 
culture, following a single dose treatment of various duration, was analyzed.  
To start, MGC seeded in 100 mm plates were treated with rHIgM22 or with two different 
non immunogenic Human IgM provided by Sigma-Aldrich and Jackson Immuno-
Research., to see if there was any morphological alteration due to the treatment. 
Photographs were taken at different time points (0, 6, 24 and 48 hours after treatment).  
No significant morphological changes in MGC culture were detectable following 
treatment with either rHIgM22 (Figure 9, Upper panel) or Human IgM provided by 
Sigma (Figure 9, Lower panel), whereas treatment with Human IgM provided by 
Jackson determined an increase in astrocytes content (Figure 9, Middle panel). 
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Figure 9.  Morphological changes due to rHIgM22 treatment. MGC culture were treated with 
rHIgM22 or with two different non immunogenic human IgMs for 6, 24 or 48 hours. The Upper 
Panel shows the MGC culture plate treated with rHIgM22. The Middle Panel shows the MGC 
culture plate treated with Jackson negative control Human IgM. The Lower Panel shows the MGC 
culture plate treated with Sigma negative control Human IgM. 
 
Lipid analysis 
Then, the lipid pattern of the cells after 24h of treatment was evaluate. Figure 10, shows 
the HPTLC analysis of  lipids obtained as described in Material and Methods section from 
MGC after single dose treatment with rHIgM22, control Human IgM provided by Sigma 
and control Human IgM provided by Jackson. Panel A shows the HPTLC analysis of 
organic phases obtained from MGC after treatment. Panel B shows the HPTLC analysis 
of alkali treated organic phases obtained from MGC after treatment. Figure 11 shows the 
HPTLC analysis of aqueous phases obtained from MGC after treatment. 
No significant difference in the lipid pattern could be observed between cells treated with 
rHIgM22 and the relative negative controls. 
Moreover, the glycerophospholipid content in MGC after 24h of treatment was analyzed 
in the organic phases, obtained after partitioning of total lipids extract and results are 
shown in Figure 12. Any differences between the glycerophospholipid content in MGC 
treated with rHIgM22 and the two relative negative controls could be observed. 
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Figure 10.  Evaluation of lipid pattern expressed by MGC after rHIgM22 treatment. MGC 
culture were treated with rHIgM22 or with two different non-immunogenic human IgMs for 24 
hours. Then, total lipids extracted from cells were subjected to a partitioning in aqueous and 
organic  phases and analyzed by HPTLC using chloroform/methanol/water 110:40:6 by volume 
as solvent system (Panel A shows the organic phases). Then, aliquots of organic phases were 
subjected to alkali treatment to remove glycerophospholipids and analyzed by HPTLC using 
chloroform/methanol/water 110:40:6 by volume as solvent system (Panel B). 
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Figure 11.  Evaluation of lipid pattern expressed by MGC after rHIgM22 treatment. MGC 
culture were treated with rHIgM22 or with two different non-immunogenic human IgMs for 24 
hours. Then, total lipids extracted from cells were subjected to a partitioning in aqueous (shows 
here) and organic  phases and analyzed by HPTLC using chloroform/methanol/ CaCl2 0.2% 
50:42:11 by volume as solvent system.  
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Figure 12.  Evaluation of lipid pattern expressed by MGC after rHIgM22 treatment. MGC 
culture were treated with rHIgM22 or with two different non-immunogenic human IgMs for 24 
hours. Then, total lipids extracted from cells were subjected to a partitioning in aqueous (shows 
here) and organic  phases. The organic phases was analyzed by HPTLC using 
chloroform/methanol/acetic acid/water 30:20:2:1 as solvent system and  visualized by sprying with 
a reagent specific to identify phosphorus. 
 
Protein analysis 
In order to investigate the effect of rHIgM22 treatment on MGC culture, also the protein 
expression, after 6, 24 and 48 of treatment, was evaluated with specific antibodies.  
Proteins expression are shown in Figure 13.   
The Src family of protein tyrosine kinases, which includes Src, Lyn, Fyn, Yes, Lck, Blk, 
and Hck, are important in the regulation of growth and differentiation of eukaryotic cells 
[313]. Src activity is regulated by tyrosine phosphorylation at two sites, but with opposing 
effects. While phosphorylation at Tyr416 in the activation loop of the kinase domain 
upregulates enzyme activity, phosphorylation at Tyr527 in the carboxy-terminal tail by 
Csk renders the enzyme less active [314]. After 24 hours of treatment, the P-Src(Y416) 
family expression in cells treated with rHIgM22 undergo to a 2-fold decrease compared 
with its expression in cells treated with Human IgM provided by Sigma. The reduction in 
the expression rate of P-Src(Y416) family in the cells treated with rHIgM22 was 3 times 
compared with that observed in Human IgM provided by Jackson (Figure 13, Panel B). 
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After 48 hours of treatment, the P-Src(Y416) family expression in cells treated with 
rHIgM22 undergo to a 1.5-fold decrease compared with its expression in cells treated 
with both Human control IgM (Figure 13, Panel C).  
As previously described, Lyn is one of the Src family members. A decrease in Lyn 
expression was detected after 24 and 48h of treatment with rHIgM22 compared only with 
Human control IgM provided by Jackson of 1.5 and 2-fold respectively (Figure 13, Panel 
B and C). 
The platelet-derived growth factor (PDGF) family consists of proteins able to regulate 
diverse cellular functions by binding a receptor named PDGFRα. PDGFRα is a member 
of the class III subfamily of receptor tyrosine kinases (RTK). All class III RTKs are 
characterized by the presence of five immunoglobulin-like domains in their extracellular 
region and a split kinase domain in their intracellular region. Ligand-induced receptor 
dimerization results in autophosphorylation in trans resulting in the activation of several 
intracellular signaling pathways that can lead to cell proliferation, cell survival, 
cytoskeletal rearrangement, and cell migration [315]. 
MGC treated with rHIgM22 showed an increase in the PDGFRα expression, proportional 
to the duration of treatment (Figure 13, Panel A, B and C). 
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Figure 13.  Evaluation of proteins expressed by MGC after rHIgM22 treatment. MGC culture were 
treated with rHIgM22 or with two different non-immunogenic human IgMs for 6, 24 and 48 hours. Then, 
proteins extracted from cells were subjected to gel electrophoresis separation and western blot analysis. As 
internal control GAPDH was evaluated. 
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aSMase activity 
Further, the effect of rHIgM22 on aSMase activity of MGC culture, following a single 
dose treatment of various duration, was assessed.  
To start, MGC have been labeled with [1-3H]Sphingosine by a pulse and chase 
experiment, as described in Material and Methods section. After 24 hours from the 
beginning of the chase, 3H-MGC were treated with rHIgM22 or with two different non-
immunogenic Human IgM provided by Sigma-Aldrich and Jackson Immuno-Research., 
for 6, 24 and 48 hours. 
Interestingly, the total aSMase activity in MGC treated with rHIgM22 was significantly 
reduced, compared to that in both Human control IgM provided by Jackson and Sigma.  
These data are shown in Figure 14. 
 
 
Figure 14.  Evaluation of aSMase activity in MGC after rHIgM22 treatment. MGC culture were treated 
with rHIgM22 or with two different non-immunogenic human IgMs for 6, 24 or 48 hours before assessing 
aSMase activity. For each timing, the enzymatic activity assessed was significant reduced in MGC treated 
with rHIgM22 compared to the relative controls. The aSMase activity was expressed as pmol/mg of 
protein/hours. Data is expressed as mean ± SD of six experiments *, p<0.05; **, p < 0.001   
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Multiple sclerosis (MS), pathological characteristics has been firs decribed by Charcot, 
Carswell, Cruveilhier and others more than 100 years ago, is considered the lead disease 
featuring demyelination [316].  
MS is the most common cause of non traumatic disability in young people, with an onset 
usually between 20-40 years of age [221], affecting 2.5 million people throughout the 
world [222]. It is characterized by inflammation, progressive demyelination and gliosis, 
axonal injury and loss. The pathological hallmarks of all the subtypes of this disease are 
focal areas, called plaques, of demyelination in the CNS, with surrounding inflammation 
and neurodegeneration [223,224].   
Despite its high prevalence, multiple sclerosis remains a challenging ailment to study. 
The aetiology is unknown, the pathophysiologic mechanisms are various, and the chronic 
and unpredictable course of the pathology represent a drawback when it comes to defining 
whether the positive effects of short-term treatment will be sustained [316]. Currently the 
most widely accepted hypothesis concerning MS pathogenesis is the autoimmune 
hypothesis:  an autoimmune inflammation is proposed to be the cause of demyelination 
and auto-reactive leukocytes could be the disease initiators [225, 226].  
Whether the immune response is the cause of the pathogenesis or simply a consequence 
of the oligodendroglial cell death, the failure of the immune system to discriminate myelin 
components from foreign antigens plays a critical role in the pathophysiology of MS.  
One of the FDA approved immunomodulatory drugs for MS, Fingolimod, is a 
sphingosine-1-phosphate (S1P) receptor modulator able to control lymphocyte trafficking 
[268]. However, it was also found to modulate resident glial cells and to increase 
remyelination efficiency [269-272]. Currently two major approaches involving a more 
direct stimulation of the remyelination process are being tested in animal models of 
demyelination.  
 The first approach involves the transplantation of cells capable of remyelination 
and is based on the evidence that transplanted glial cells myelinate in the CNS 
following their introduction in the developing CNS of rodents with myelin 
mutations or with toxin-induced demyelination [273, 274].  
 the second approach being tested in animal models of demyelination involves the 
promotion of repair by the resident stem- and precursor-cell populations in the 
adult CNS, through the administration of growth, trophic, and neuroprotective 
factors [276].  
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An alternative therapeutic approach is the use of CNS reactive antibodies to promote 
remyelination [280]. Two of these remyelination promoting antibodies are represented by 
BIIB033 and the recombinant human IgM22 (rHIgM22). The first is an anti-LINGO-1 
IgG acting on LINGO-1, a protein known to inhibit remyelination via RhoA activation, 
and is currently being tested in a Phase II study in RRMS (ClinicalTrial.gov: 
NCT01864148). The second antibody, instead, is an IgM sharing several features with 
naturally occurring antibodies and is currently undergoing a phase I clinical trial aimed 
to evaluate safety and tolerability in relapsing MS patients (ClinicalTrial.gov: 
NCT02398461), after the first phase I clinical trial in MS patients was completed 
successfully (ClinicalTrial.gov: NCT01803867). 
In particular, rHIgM22 was first identified through the screening of human serum of a 
patient with Waldenström macroglobulinemia as a myelin-binding antibody and it’s able 
to promote significant remyelination in vivo [291]. The actual target and mechanisms of 
rHIgM22 are still under investigation however several pieces of evidence suggest that the 
antigen recognized by this antibody might be a plasma membrane lipid, possibly sulfatide 
[294, 295]. Moreover, existing literature suggests that the binding target of rHIgM22 
could be associated with detergent-resistant membranes (DRM)/lipid rafts and that 
rHIgM22 biological activity depends on lipid raft organization [294, 295]. Furthermore, 
literature strongly suggests that rHIgM22 biological activity, responsible for its myelin-
repair promoting activity, could require a multimolecular complex organizing Lyn and 
the cell surface molecules integrin αvβ3 and PDGFRα [296, 297]. Taken together, these 
observations have led to hypothesize that rHIgM22, through its pentameric structure, 
could mediate the clustering of a lipid antigen and stabilize lipid rafts domains. Moreover, 
it could determine the reorganization of Lyn, integrin αvβ3 and PDGFRα to form a 
signaling complex which, in turn, promotes OPC survival and proliferation [295, 296]. In 
isolated OPCs, PDGF is required for rHIgM22-mediated inhibition of apoptotic signaling 
and differentiation. PDGF is produced by neurons and astrocytes and stimulates OPC 
proliferation and promotes OPC survival both in vivo and in vitro. Indeed, IgM-mediated 
OPC proliferation is detectable only in cultures containing substantial amounts of 
astrocytes, microglia and OPCs (mixed glial cultures) but not in highly enriched OPC 
population[297]. 
Previous analysis, performed in our laboratory, of the binding of rHIgM22 to sulfatide 
revealed that rHIgM22 is able to recognize sulfatide in vitro, and that this binding is 
specific. Moreover, our data suggests that the binding of rHIgM22 to sulfatide might be 
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affected by the composition of the lipid microenvironment (data not shown). These data 
are in agreement with evidence reported in the literature, which shows that the lipid 
environment might play a role in the determination of the surface topology of sulfatide 
[317, 318].  
The aim of this study was to analyze the plasma membrane lipid rafts composition in 
MGC in order to evaluate the effects exerted by rHIgM22 on these cells after single dose 
treatment of various duration.  
The analysis of the lipids and proteins distribution in MGC fractions, obtained after 
discontinuous sucrose gradient centrifugation of cells previous labeled with [1-
3H]sphingosine and lysed in the presence of Triton X-100, revealed that sphingolipids 
(ceramide, glucosylceramide, sphingomyelin and gangliosides) were more represented in 
the DRM fraction and slightly represented in the HD fraction; differently, phospholipids 
(phosphatididylethanolamine and phosphatidic acid) took an opposite distribution. 
Moreover, both sphingomyelin and gangliosides were enriched in the DRM fraction. So, 
as expected, the DRM fraction was highly enriched in sphingolipids, and relatively 
depleted of glycerophospholipids [301]. The major amount of glycerophospholipids 
existed in HD fraction.  
Furthermore, it has been reported that sphingolipid-enriched domains, that are also 
enriched in cholesterol, are emerging as membrane compartments with relevant 
biological functions. Unlike what was expected, in MGC cholesterol was more 
represented in the HD fraction than in DRM fraction. In fact, about 50% of cellular 
cholesterol was associated with HD fraction and only about 25% of cellular cholesterol 
was associated with DRM fraction [301]. 
Glycosphingolipids clusters at the cell surface membrane interact with functional 
membrane proteins such as integrins, growth factor receptors, tetraspanins, and 
nonreceptor cytoplasmic protein kinases to form "glycosynaptic domains" controlling cell 
growth, adhesion, and motility. 
Western blotting analysis performed on the MGC gradient fractions samples revealed that 
integrin (heterodimeric cell surface receptors that play a pivotal role in cell adhesion, 
growth and survival), in particular integrin αv, was localized in HD fraction. Likewise, 
Akt (protein kinase activated by insulin and various growth and survival factors, that 
promotes cell survival by inhibiting apoptosis through phosphorylation and inactivation 
of several targets), was localized in HD fraction. On the other hand, Lyn (one of the Src 
family members), Caveolin 1(the principal structural components of the 
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cholesterol/sphingolipid-enriched plasma membrane microdomain caveolae, involved in 
diverse biological functions, including vesicular trafficking, cholesterol homeostasis, cell 
adhesion, and apoptosis) and PrP(SAF32) (highly conserved protease-sensitive 
sialoglycoprotein of unknown function which is endogenously expressed in brain, 
anchored to the external surface of the cell membrane by glycosyl-phosphatidylinositol) 
were mainly localized in DRM fraction. 
Furthermore, the morphological evaluation of the effects exerted by treatment with 
rHIgM22 on MGC culture revealed no significant change compared with two different 
non immunogenic Human IgM. In the same way, no significant difference in the lipid 
pattern and glycerophospholipids content could be observed between cells treated with 
rHIgM22 and the relative negative controls. 
On the other hand, the rHIgM22 treatment exerted an effect on the protein expression in 
MGC culture compared with the two negative control. In particular, the P-Src(Y416) 
family,  tyrosine kinases important in the regulation of growth and differentiation of 
eukaryotic cells, expression in cells treated with rHIgM22 decreased if compared with its 
expression in cells treated with Human control IgM, higher after 24 hours of treatment. 
Moreover, also a decrease in Lyn expression was detected after 24 and 48h of treatment 
with rHIgM22. On the contrary the PDGFRα expression undergoes to an increase, 
proportional to the duration of treatment. This is interesting because PDGFRα has been 
proposed as one of the members of the signaling complex through which rHIgM22 exterts 
its biological activity. In fact, literature strongly suggests that rHIgM22 biological activity 
is mediated by the reorganization of Lyn, integrin αvβ3 and PDGFRα at the cell surface 
to form a signaling complex triggering Lyn activation which, in turn, promotes 
oligodendrocyte precursor cells (OPCs) survival and proliferation [296, 297].  
Finally, the total aSMase activity in MGC treated with rHIgM22 was significantly 
reduced, compared to that in both Human control IgM, with consequent reduced ceramide 
generation. In fact it has been reported that, in oligodendrocytes, activation of Lyn 
promotes cell survival by suppressing acid sphingomyelinase activity, and ceramide 
generated by the action of ASMase represents not only an important pro-apoptotic signal, 
but also a signal for the re-arrangement of sphingolipid-rich signaling platforms.  
And this effect might also be relevant from the therapeutic point of view, in fact ASMase 
and its enzymatic product, ceramide, have been shown to be expressed at higher levels in 
human MS lesions compared to unaffected brain tissue and deficiency or blockade of the 
ASMase/Cer system significantly improves myelin repair after demyelination [319]. 
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Summarizing, the data so far collected demonstrate that the DRM fraction obtained from 
MGC was enriched in sphingolipids, in particular sphingomyelin and gangliosides 
together with Lyn, Caveolin 1 and PrP(SAF32). On the contrary, phospholipids, in 
particular phosphatididylethanolamine and phosphatidic acid are enriched in the HD 
fraction, together with integrin αv and Akt. 
Furthermore we observed that rHIgM22 exerted an effect on the expression of P-
Src(Y416) family and Lyn, that show a significant decrease, and PDGFRα that shows a 
significant increase. Moreover, the rHIgM22 treatment also induces a decrease in the 
activity of the aSMase.    
In the light of these data we hypothesize that the treatment with IgM22 could elicit 
biological responses mediated by alterations of lipid-dependent membrane organization 
which result in a reorganization of Lyn, integrin αvβ3 and PDGFRα at the cell surface to 
form a signaling complex. The formation of this complex triggers Lyn activation which 
in turn promotes oligodendrocyte precursor cells (OPCs) survival and proliferation and 
an inhibition of the pro apoptotic signaling. Based on the data we obtained we hypothesize 
that the increased activation of Lyn could determine a decrease in ASMase activity and 
consequently in ceramide generation, thus inhibiting pro-apoptotic signaling and/or 
organization of sphingolipid-dependent signaling platforms. 
 Understanding whether rHIgM22 effect on remyelination involves a lipid-organized 
membrane complex, and the exact identity of the antigen involved and their organization 
in this complex is of great importance. The identification of the binding targets of this 
antibody, able to promote remyelination in validated mouse models of MS, and the 
characterization of their membrane microenvironment could significantly contribute to 
the reveal the signaling mechanisms underlying the biological activity of rHIgM22. This, 
in turn, would allow to obtain a better comprehension of the process of (re)myelination, 
and of the molecular mechanism involved in the pathophysiology of multiple sclerosis, 
thus allowing to define new potential therapeutic targets. 
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